REVIEW

Check for updates

Medicinal chemistry perspective of pyrido[2,3-d]pyrimidines as anticancer agents

Adarsh Kumar,†[a] Kuber Kumar Bhagat,†[a] Ankit Kumar Singh, [ID][a]
Harshwardhan Singh,[a] Tanuja Angre,[a] Amita Verma, [ID][b] Habibullah Khalilullah,[c]
Mariusz Jaremko, [ID][d] Abdul-Hamid Emwas[e] and Pradeep Kumar [ID]*[a]

Cancer is a major cause of deaths across the globe due to chemoresistance and lack of selective chemotherapy. Pyrido[2,3-d]pyrimidine is an emerging scaffold in medicinal chemistry having a broad spectrum of activities, including antitumor, antibacterial, CNS depressive, anticonvulsant, and antipyretic activities. In this study, we have covered different cancer targets, including tyrosine kinase, extracellular regulated protein kinases – ABL kinase, phosphatidylinositol-3 kinase, mammalian target of rapamycin, p38 mitogen-activated protein kinases, BCR-ABL, dihydrofolate reductase, cyclin-dependent kinase, phosphodiesterase, KRAS and fibroblast growth factor receptors, their signaling pathways, mechanism of action and structure–activity relationship of pyrido[2,3-d]pyrimidine derivatives as inhibitors of the above-mentioned targets. This review will represent the complete medicinal and pharmacological profile of pyrido[2,3-d]pyrimidines as anticancer agents, and will help scientists to design new selective, effective and safe anticancer agents.

1 Introduction

Cancer is the explosive growth of abnormal cells that typically grow beyond their original boundaries, invade surrounding areas, spread to other organs, and result in metastasis, which is one of the main causes of cancer-related death,and second most common cause of death across the globe. Around 10.0 million cancer-related fatalities (9.9 million excluding nonmelanoma skin cancer) and 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) were estimated in 2020 across the globe. The most lethal malignancies include lung (1.8 million), colorectal (935 000), liver (830 000), stomach (769 000), and breast cancer. The most frequent cancers worldwide are lung (2.2 million), breast (2.09 million), colorectal (1.9 million), prostate (1.28 million), skin (1 million), and stomach

(1 million) (627 000).[1] Cancer is the Latin term meaning crab. Because of the crab-like tenacity, a malignant tumor often appears to grab the tissues it invades, and the ancients used the term to indicate a malignancy.[2] Cancer cells (defined by their uncontrollable growth and invasion of other tissues) do not show the same growth average as a normal heathly cell. Normal cells multiply and expand, controlled to produce additional cells as required to maintain a healthy body. Cells die as they grow old or are damaged and are replaced by new cells. Cancer cells, rather than dying, continue to proliferate and generate new, aberrant cells. Normal cells cannot invade (grow into) other tissues. The other cells can combine to form a mass of tissues known as a tumor. Not all tumors are cancerous; they might be benign (not cancerous) or malignant (cancerous).[3] The worldwide burden of cancer is anticipated to rise significantly due to population growth, age, and increase in risk factors like smoking, inactivity, poor food, and infections that cause cancer. It is well established that cancer diagnosis and treatment have substantial and long-term consequences on both patient and caregiver physical, emotional, and spiritual well-being.[3,4]

1.1 Pyrido[2,3-d]pyrimidine

Purines, quinazolines, pteridines, and pyrido-pyrimidines are examples of bicyclic nitrogen-containing heterocyclic compounds that are well-known pharmacophores in medicinal chemistry. Examples of commercial medications with a bicyclic main structure include the tyrosine kinase inhibitors gefitinib and erlotinib, and both are quinazoline derivatives. Both of them are used to manage non-small cell lung cancer. Pyrido[2,3-

[a]*Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Ghudda, Bathinda 151401, India. E-mail: pradeepyadav27@gmail.com*

[b]*Bioorganic and Medicinal Chemistry Research Laboratory, Department of Pharmaceutical Sciences, Sam Higginbottom University of Agriculture Technology and Sciences, Prayagraj, 211007, India*

[c]*Department of Pharmaceutical Chemistry and Pharmacognosy, Unaizah College of Pharmacy, Qassim University, Unayzah, 51911, Saudi Arabia. E-mail: h.abdulaziz@qu.edu.sa*

[d]*Smart-Health Initiative and Red Sea Research Center, Division of Biological and Environmental Sciences and Engineering, King Abdullah University of Science and Technology, P.O. Box 4700, Thuwal 23955-6900, Saudi Arabia. E-mail: Mariusz.jaremko@kaust.edu.sa*

[e]*King Abdullah University of Science and Technology, Core Labs, Thuwal 23955-6900, Saudi Arabia. E-mail: abdelhamid.emwas@kaust.edu.sa*

† Equal contribution.

Fig. 1 Pharmacological activities of the pyrido[2,3-d]pyrimidine derivatives.

d]pyrimidines have been studied extensively as quinazoline analogs.[5,6] Pyrido[2,3-d]pyrimidines have shown antitumor, antibacterial, CNS depressive, anticonvulsant, antipyretic, and analgesic effects, as shown in Fig. 1.[6] Particularly, pyrido[2,3-d] pyrimidines have been shown to be effective against *Toxoplasma gondii* and *Pneumocystis carinii* (tg) culture of tumor cell lines, and the activity is attributed to dihydrofolate reductase inhibition.[7–9] Due their diverse anticancer or antiproliferative properties, pyrido[2,3-d]pyrimidine derivatives were great interest of reseachers working in this field.[10,11] Fusing a pyridine and a pyrimidine ring results in pyridopyrimidines, ortho-fused bicyclic heterocyclic structures. Pyridopyrimidines (1,3,8-tri-azanaphtalenes) are one of the four isomeric pyridopyr-imidines.[12,13] Because of their proximity to DNA bases, such structures are included in the favored heterocyclic scaffolds hypothesis for drug development, which was suggested by

Evans in the late 1980s and recently refined by Altomare.[14,15] Pyrido[2,3-d]pyrimidine is a favored heterocyclic scaffold that can act as ligands for various receptors in the body.[16]

2 Synthetic strategies of pyrido[2,3-d] pyrimidines

Various methods for developing pyrido[2,3-d]pyrimidines have been previously reported *via* condensation techniques and pyridine annelation reactions, in solid as well as solution phase. In 1993, Kisliuk *et al.* described the synthesis of pyrido[2,3-d] pyrimidine-2,4-diamines as shown in Fig. 2. They synthesized precursor (3) in the presence of RANEY® Ni (70%) in acetic acid by deductive condensation of 6-cyano-5-methyl-pyrido[2,3-d] pyrimidine-2,4-diamine (2) with 3,4,5-trimethoxyaniline (1), which was then methylated at the N_{10} position by reductive


**Fig. 2** Scheme for the synthesis of pyrido[2,3-d]pyrimidine derivative (4).

Fig. 3 Scheme for the synthesis of pyrido[2,3-d]pyrimidine diamine derivative (9).

alkylation with formaldehyde and sodium cyanoborohydride.[17,18]

They also created a different method to synthesize pyrido[2,3-d]pyrimidine-2,4-diamines (9) by mixing 2,4,6-triaminopyrimidine (5) with the sodium salt of nitromalonaldehyde and obtained create the 2,4-diamino6-nitropyrido[2,3-d]pyrimidine (7) in a single step. This compound was subsequently reduced to its 6-amino homolog by RANEY® Ni using DMF. By using several aldehydes in reductive amination, the desired product 8 was produced (ArCHO = 3,4,5-trimethoxybenzaldehyde). In the final step, formaldehyde was used to N-methylate 8 in the presence of sodium cyanoborohydride (Fig. 3).[18,19]

N6-[(2,5-dimethoxyphenyl)methyl]-N6-methylpyrido[2,3-d]pyrimidine was produced by Queener et al. In order to get the necessary 2,4,6-triaminoquinazoline, the 2,4-diamino-6-nitroquinazoline (7) was reduced with hydrogen and RANEY® nickel around 30–35 psi (10). Then, 2,5-dimethoxybenzaldehyde (ArCHO) was added to produce the N₉–H precursor (11). Using sodium cyanoborohydride, the reductive N₉-alkylation process was used to produce the end product. Queener et al. also investigated the biological effects of compound 12 as a lipophilic inhibitor of dihydrofolate reductase.[20] Piritrexim was first synthesized by Grivsky et al. possessed anti-parasitic, anti-folate, anti-psoriatic, and anti-tumor characteristics. Piritrexim suppressed dihydrofolate reductase (DHFR) and had


Fig. 4 Scheme for the synthesis of pyrido[2,3-d]pyrimidine derivative (15).

Fig. 5 Scheme for the synthesis of pyrido[2,3-d]pyrimidine derivatives.

anticancer effects in rats with carcinosarcoma. Compared to certain analogs, Piritrexim has the advantage of not acting as a histamine metabolism inhibitor, reducing the danger of adverse metabolic effects.[21] In the presence of a combination of piperidine and glacial acetic acid, 2,5-dimethoxybenzaldehyde (10) was reacted with ethyl acetoacetate in refluxing benzene to produce ethyl-acetyl-(2,5-dimethoxyphenyl) acrylate (11). The latter was subsequently hydrogenated with 5% Pd/C (catalyst) to produce the required ethyl-acetyl-(2,5-dimethoxyphenyl) propionate (12). Then, 12 was condensed using 2,4,6-triaminopyrimidine in diphenyl ether at 195–230 °C. 2,4-Diamino-7,8-dihydro-6-(2,5-dimethoxybenzyl)-5-methyl -7-oxopyrido[2,3-d]pyrimidine (13) was treated with a 1 : 1 combination of N,N-dimethylformamide thionyl chloride to produced -5-methyl-pyrido[2,3-d]pyrimidine2,4-diamine (14). The hydrogenolysis of 14 with Pd/C in the presence of potassium hydroxide produced the desired PTX (15) (Fig. 4).[18,21]

Blankley et al. synthesized 8-methyl-2-phenylamino-6-thiophene-2-yl-8H-pyrido-[2,3-d]pyrimidin-7-one (22) and 6-(biphenyl-4-yl)-8-methyl-2-phenylamino-8H-pyrido-[2,3-d] pyrimidin-7-one (23) by treating 4-chloro-5-cyano2-methylsulfanyl-pyrimidine (16) with methylamine (17). In the presence of a catalytic quantity of strong hydrochloric acid, the 2-methyl sulphide group of 17 was replaced with aniline, yielding compound 18. The aldehyde (19) was obtained by reducing the nitrile group of 18 with diisobutylaluminum hydride and then hydrolyzing it. The condensation of 19 with 2-thiopheneacetonitrile or 4-biphenylacetonitrile with 2-ethoxyethanol and sodium hydride, respectively, yielded the pyridopyrimidin-7-imines 20 and 21. Compounds 22 and 23 were obtained via acetylation of the imines followed by acid hydrolysis (Fig. 5).

In order to synthesize intermediate esters (25), ethyl 4-chloro-2-methylthiopyrimidine-5-carboxylate (24) was combined with several amines. Alcohols (26) were then


Fig. 6 Scheme for the synthesis of pyrido[2,3-d]pyrimidine derivatives.

Fig. 7 Scheme for the synthesis of pyrido[2,3-*d*]pyrimidine derivatives.

converted to 4-aminopyrimidine-5-carboxaldehydes through oxidation (**27**). To make the core pyrimidinopyridones, aldehydes (**27**) were condensed with appropriately substituted acetates. In order to synthesize the desired molecules (**30**), the methylthio groups of pyrimidinopyridones (**28**) were oxidized to produce the representative sulfones (**29**). The most frequent path was needed for 8-substituent chains since they were more intricate than straight chains (Fig. 6)[22]

The synthesis of the reduced form of the target heterocycle in a highly regioselective manner has been reported using 6-aminouracil derivatives as the enamine component in a Michael or Hantzsch-type condensation. This strategy has several advantages over current methods, including using readily available alkynones as Michael acceptors, effectively eliminating the need for subsequent oxidation, and providing pyrido[2,3-*d*]pyrimidine derivatives directly without purification and with total regiochemical control.[23] Victory and colleagues investigated a heterocyclic system that can be produced in a multistep sequence using 2-methoxy-6-oxo-1,4,5,6-tetra-hydropyridin-3-carbonitrile intermediates [created by reacting an α,β-unsaturated ester (**31**) with malononitrile (**32**, G = CN) in MeOH/NaOMe]. Because pyridones **33** include a highly reactive

methoxy group, they are suitable substrates for a subsequent nucleophilic substitution or condensation processes. By treating pyridones **33** with amidine systems **35** (R$_4$ = NH$_2$, H, Me, Ph), they have created extensive procedures for the synthesis of bicyclic heterocycles such as pyrazolo[3,4-*b*]pyridines, 1,6-naphthyridines, and 4-amino-pyrido[2,3-*d*]pyrimidines **36** (R$_3$ = NH$_2$). In another study, they described an acyclic variation of the protocol for synthesizing pyridopyrimidines **36** (R$_3$ = NH$_2$), focusing on isolating the corresponding Michael adduct **34** (G = CN). This allowed them to also produce 4-oxopyrido[2,3-*d*]pyrimidines **36** (R$_3$ = OH) by treating intermediates **34** (G = CO$_2$Me), which were produced by the Michael addition of acrylate (**31**) and methyl cyanoacetate (**32**, G = CO$_2$Me), with an amide analog (**35**). They showed that pyrido[2,3-*d*]pyrimidines **36** may be synthesized in a single step using a microwave-assisted cyclocondensation of α,β-unsaturated ester, amidine, with malononitrile/cyanoacetate (Fig. 7).[24]

Another approach reported in the literature is using nanocrystalline MgO in the reaction of 6-aminouracil, 6-amino-2-thiouracil, or 6-amino-1,3-dimethyluracil with malononitrile and aldehydes in water at 80 °C to produce a series of pyrido[2,3-*d*]pyrimidine derivatives in high yields.[25] In a different

Method A:- MW-DMF (250 W, 120°C).

Method B:- 10 mol% diammonium hydrogen phosphate (DAHP), H$_2$O:EtOH, 2:1, reflux.

**Fig. 8** General method of synthesizing pyrido[2,3-*d*]pyrimidine derivatives.

Fig. 9   Scheme for the synthesis of pyrido[2,3-d]pyrimidine derivatives.

strategy, they demonstrated an efficient one-pot three-component reaction of aromatic aldehydes, malononitrile, and (6)-aminouracil and MWI for the synthesis of pyrido[2,3-d] pyrimidines using microwave irradiation (method A) and also in the presence of catalytic amounts of DAHP (10 mol percent) aqueous ethanol under reflux (method B) (Fig. 8).[26]

When the reaction of aldehyde, 2,6-diaminopyrimidin-4-one (38), and malononitrile (39) was performed in the presence of glycol under microwave irradiation, the derivative (40) was generated in good yields. Aldehyde (37), 2,6-diaminopyrimidin-4-one (38), and ethyl cyanoacetate (41) were carried out under the same conditions. When 2-cyanoacetamide was used in place of ethyl cyanoacetate (41), dehydrogenation of (42) was also accomplished (43). Meldrum's acid (45), (37), and (38), used as starting materials for microwave irradiation, produced the required compounds (46) in significant amounts (Fig. 9).[27]

3   Molecular targets of pyrido[2,3-d] pyrimidine derivatives

Many antitumor activities have been reported for pyrido[2,3-d] pyrimidines, which could be attributable to the inhibition of various enzymes involved in carcinogenesis.[9]

3.1   Tyrosine kinase

Tyrosine kinases are essential components of the signaling cascade that controls cell division, metabolism, migration, and the death of cells. Tyrosine kinases use ATP to catalyze the phosphorylation of particular tyrosine residues in their protein targets.[28] Tyrosine kinases play an essential role in several stages of the emergence and spread of cancer. Tyrosine kinase signal transduction typically regulates excessive proliferation or increases apoptotic sensitivity. These signaling pathways are frequently genetically or epigenetically changed in cancer cells to provide specific benefits to cancer cells. As a result, it is no surprise that abnormally increased signaling from tyrosine kinases gives these enzymes a dominant oncoprotein status, resulting in signaling network failure.[29]

3.1.1   Biological pathway and inhibition of tyrosine kinase.
Receptor tyrosine kinase (RTKs) are usually activated by ligands that target specific receptors. Growth factor ligands bind to RTK's extracellular regions, and the receptor activation is carried out by ligand-induced dimerization or oligomerization.[30] Ligand attached to the extracellular domain stabilizes the generation of active dimers, which activates protein tyrosine kinases. The concentration of RTKs is increased by receptor oligomerization, enabling effective transphosphorylation of

Fig. 10 Mechanisms of RTK activation. (A) RTK activation. (B) Potential gain-of-function mutations and the signal inhibition. (C) Genetic amplification leads to the transcription, and TKI leads to the inhibition of diseases causing signals.

tyrosine residues inside the activation loop of the catalytic domain. For most RTKs, the resulting conformational alterations allow *trans*-autophosphorylation of each TKD and the release of *cis*-autoinhibition (Fig. 10).[31,32]

Genetic amplification is the principal mechanism that leads to the overexpression of RTKs and transcription enhancement.[33,34] SH2 domain proteins interact with phosphorylated receptors and become phosphorylated as well. The growth factor Ras/Raf/mitogen-activated protein map phosphorylated cascade then connects with the substance of the g-protein system, allowing the cell to migrate and express itself.[30,35]

3.1.2 Mechanism of action of tyrosine kinase inhibitors. Several amino acids of substrate enzymes are phosphorylated by tyrosine kinases, leading to different changes in the downstream cellular biology and signaling. TKs can alter cell growth, migration, differentiation, apoptosis, and death by triggering downstream signal transduction. Constitutive activation or inhibition, whether caused by mutations or other methods, can result in dysregulated signal cascades, which can lead to cancer and other diseases.[35,36] The tyrosine kinase inhibitors inhibit this dysregulated signal cascade and block transcription in both genetic amplification and mutation, leading to the disease-causing signals.[36] The compounds **47–51** showed excellent activity against various kinases, including TKs, PI3K, and CDK4/6. In molecule **47**, the presence of dichloro and tertiary amine increased the activity. In molecule **48**, piperazine with amine linkage and acetyl group at pyridine ring increased the activity, thiophene, phenyl with fluorine

Fig. 11 Reported pyrido[2,3-d]pyrimidine as kinase inhibitors.

atom were responsible for activity in **49**, presence of methoxy and morpholine were necessary for activity in molecule **50**, also other triazole rings in **51** enhanced the activity (Fig. 11).[37–40]

In 2018, Elzahabi *et al.* successfully synthesized substituted pyrido[2,3-d]pyrimidines and tested their ability to inhibit the growth of five cancer cell lines. Pyrido[2,3-d]pyrimidines, were found to have significant inhibitory effects against a variety of kinases, including TKs, PI3K, and CDK4/6.[9]

3.1.3 Structure activity relationship of tyrosine kinase inhibitors. According to the structure–activity relationships of the screened products, presence of carbonyl at C-2 of pyrido[2,3-d]pyrimidine derivatives (**52–56**) provided the maximum anticancer activity. Particularly **52** and **53**, which had (4-CH$_3$-phenyl) and (4-chlorophenyl) at C-5 and C-7, respectively, shared the same pyridopyrimidine scaffold. Compound **53** containing 3-methyl-5-oxopyrazolyl moiety of showed strong anticancer efficacy against prostate, colon, and liver malignancies. The anticancer action was switched from anti-colon to anti-prostate cancer when the methylpyrazolone moiety in **53** was replaced with aminopyrazolone in **54** (Fig. 12 and 13).

In the same way, adding a steric bulky group to **56** and **57** reduced its anticancer efficacy. Converting the thioxo group in **58** to the hydrazide moiety in **59** significantly enhanced the anti-hepatic cancer activity. The electronic component was able to have a positive impact on anticancer activity due to the hydrophilic electron-rich nature of the hydrazide molecule.[9]

A novel class of substituted pyrido[2,3-d]pyrimidinones was investigated for their *in vitro* anticancer efficacy. Compounds **52** and **55** were more effective (IC$_{50}$ = 0.3 μM) than doxorubicin in the HepG-2 cell line. In addition, compound **59** was approximately equivalent to doxorubicin (IC$_{50}$ = 0.6 μM). Compounds **60** and **52** were having higher activity than doxorubicin (IC$_{50}$ = 5.47, 6.6, and 6.8 μM, respectively) in a cellular screening on PC-3. The activity of **60**, **52**, and **53** was two-fold as that of doxorubicin in the HCT-116 cell line (IC$_{50}$ of 6.9, 7, 5.9 μM, and 12.8 μM, respectively). Synthesized compounds showed significant growth inhibitory effects in HepG-2, HCT-116 as well as PC-3 cell lines with reference to doxorubicin, but on MCF-7 and A-549 cancer cells showed comparetively low activity. PDGFR β, EGFR, and CDK4/Cyclin D1 kinases were all inhibited by the potent anticancer molecule **52** (Fig. 13).[9]

Fig. 12 SAR of pyrido[2,3-*d*]pyrimidine derivatives.

Pyrido[2,3-*d*]pyrimidine is a vital core known to play a role in many active compounds with diverse activities, particularly chemotherapeutic, which may be capable of inhibiting cyclin-dependent kinase (CDK). For example, The US Food and Drug Administration has authorized the CDK4/6 inhibitor palbociclib (**61**), which is used to treat breast cancer. In addition, 2,4-

Fig. 13 Pyrido[2,3-*d*]pyrimidine derivatives reported as tyrosine kinase inhibitors.

Fig. 14 Pyrido[2,3-*d*]pyrimidine derivatives reported as anticancer agents.

diaminopyrido[2,3-*d*]pyrimidine (**62**) is a promising anticancer drug with dose-dependent antiangiogenic and proapoptotic actions through induction of 2 separate signaling pathways, notably G2/M cell cycle arrest as well as induction of apoptosis by encouraging caspase-3 activation and DNA fragmentation. Furthermore, compound **63** showed remarkable anticancer activity against prostate (PC-3) and lung (A-549) cancer cells with IC_{50} values of 1.54 and 3.36 μM, respectively. Furthermore, at submicromolar concentrations (0.36, 0.41 μM, respectively), the fused triazolopyridopyrimidine (**64**) showed greater efficacy against both cell lines, causing cell cycle arrest by increasing the cell cycle inhibitor p21 and cancer cell death by activating caspase-3 (Fig. 14).[41]

Another study discovered a highly potent tyrosine kinase inhibitor (**65**) having IC_{50} values of 1.11, 0.13, 0.45, and 0.22 μM against the tyrosine kinases, PDGFr, FGFr, EGFr, and c-src respectively.[42] PD180970, the derivative of pyrido[2,3-*d*]pyrimidine, acted by inhibiting ATP-competitive protein tyrosine kinase. Dorsey *et al.* found that in human K562 chronic myelogenous leukemic cells, **66** reduced *in vivo* tyrosine phosphorylation of p210Bcr-Abl (IC_{50} = 170 nM), the p210Bcr-Abl substrates Gab2 and CrkL (IC_{50} = 80 nM).[43] Compounds **65** and **66**, with IC_{50} values of 115.38 nM and 726.25 nM, were the most effective direct CDK6 inhibitors in the series. Compound 65 caused apoptosis 1.9-fold in PC-3 cells and 1.8-fold in MCF-7 cells in the apoptotic assay. The molecule **65** triggered apoptosis primarily by activating caspase-3. Compound **66**, on the other hand, promoted apoptosis primarily through the intrinsic route, with direct inhibition of CDK6.[44] Shi *et al.* proposed a new class of CDK4/6 inhibitors: imidazo[1′,2′:1,6]pyrido(2,3-*d*)

pyrimidine analogs.[44,45] In the Colo-205 as well as U87MG cell lines, CDK4/6 was found to be effectively suppressed by compounds **70** and **71**. The equipotent of palbociclib and abemaciclib, compounds **70** and **71** significantly inhibited CDK4/D3 (IC_{50} = 0.8 nM and 2.7 nM, respectively) and CDK6/D3 (IC_{50} = 2.0 nM and 4.8 nM, respectively). The acetyl and iso-propyl moieties at C_6 and C_8 positions (compound **70**) represented 2.5 more possible biological activities for CDK4/cyclinD3 than CDK6/cyclinD3.[45] Changes to the functional group *tert*-butyl at the C_8-substituent (compound **71**) did not affect CDK4/6 targeting bioactivity. Compounds **70** and **71** showed favorable antiproliferative effects, remarkable metabolic properties, useful pharmacokinetic features, and significant tumour growth inhibitions with manageable toxicity in Colo-205 and U87MG xenograft models (Fig. 15).[45]

3.2 Extracellular signal-regulated kinase and Phospatidylinositol-3 kinaseα

3.2.1 Extracellular regulated protein kinases (ERK). A serine/threonine protein kinase known as ERK1/2 (extracellular signal-regulated kinase) is frequently found in eukaryotic cells. It belongs to the family of MAPK (mitogen-activated protein kinases). The transfer of signals from surface receptors to the nucleus is significantly aided by ERK1/2. Apoptosis, cell proliferation, differentiation, and other activities are regulated by activated ERK1/2, which phosphorylates substrates in the cytoplasm or nucleus and causes the production or activation of particular proteins.[46]

3.2.2 Phospatidylinositol-3 kinase. Many cancers, including breast, gastric, ovarian, colorectal, prostate, glioma,

Fig. 15 Pyrido[2,3-d]pyrimidine derivatives reported as anticancer agents.

and endometrial cancers, have altered or amplified the activity of the critical intracellular signalling system known as PI3K (phospatidylinositol-3 kinase, or PI3K). PI3K signalling is a viable therapeutic target since it is crucial for cancer cell survival, angiogenesis, and metastasis. Clinical trials employing PI3K inhibitors are continuing and have already been completed to identify effective PI3K inhibitors that could overcome resistance to existing treatments.[47] Critical physiological and pathological processes like metabolism, cell development, proliferation, angiogenesis, and metastasis are influenced by PI3K/AKT signalling and contribute to the progression of tumours.[48,49] PI3K proteins are categorized into three major classes based on the structural characteristics of the proteins as well as the peculiarities of the substrates (I, II, and III). Class, I PI3Ks are classified into subtypes A and B based on how they are regulated. Class IA PI3Ks combine their regulatory (p85, p85, p55, p55, and p50) and catalytic (p110, p110, p110) subunits to form dimers.[50]

3.2.3 ERK2 and PI3Kα. The combined inhibition of the MAPK and PI3K signalling pathways has been identified as a viable cancer therapy that effectively overcomes the drug resistance of MAPK signalling pathway inhibitors.[51]

Zhang *et al.* reported the scaffold-hopping synthesis of ERK/PI3K dual inhibitors by replacing 1*H*-pyrazolo[3,4-*d*]pyrimidine scaffold with pyrido[3,2-*d*]pyrimidine. Compound **73** with

pyrido[3,2-*d*]pyrimidine scaffold exhibited suitable inhibitory activities on ERK2 and PI3Kα, while **72** with pyrido[2,3-*d*]pyrimidine scaffold had 1.8 and 15.1% inhibitory activity at the concentration of 1 μM on ERK2 and PI3Kα respectively (Fig. 16).[51]

Compounds **73–75** were foundd to be dual inhibitors of ERK2 and PI3K-α. Compound **74**, a potent and very effective ERK and PI3K dual inhibitor, was discovered during preliminary SAR study. Compound **74** had modest ERK and PI3K inhibitory and anti-proliferative properties. Although **74** had only acceptable pharmacokinetic characteristics in SD rats, with a moderate half-life ($t_{1/2}$ = 2.32 h) after intravenous treatment, it displayed significant anticancer activity *in vivo* in an HCT-116 xenograft model without eliciting obvious adverse consequences.[51]

3.3 Antitumor activity

Literature review revealed, Piritrexim (**76**), and its analogues 77–**82** (having pyrido[2,3-*d*]pyrimidine pharmacophore) showed excellent antitumor activity (Fig. 17).[27,52–61]

Gineinah *et al.* designed and synthesized pyrido[2,3-*d*]pyrimidine derivatives; this scaffold was then hybridized with one or more heterocyclic moieties (piperazines or triazoles).[62] Despite structural alterations to the beginning molecule **83**, the examined compounds' principal moiety (pyridopyrimidine) led

72

73-75

Sr. No.	R_1	R_2	ERK2 IC$_{50}$ (nM)	PI3Kα IC$_{50}$ (nM)
73			89	38
74			73	59
75			83	824

Fig. 16 Pyrido[2,3-*d*]pyrimidine and pyrido[3,2-*d*]pyrimidine derivatives as dual inhibitors of ERK2 and PI3Kα.

to the conservation of biological activity. While adding the *N*-phenylthiosemicarbazide moiety, compound **85**, at position five of the pyridopyrimidine, increased activity compared to carbohydrazide **84**, adding the electron-withdrawing fluoro group to compound **86** at position four of the phenyl ring decreased activity, transferring the ester to acid hydrazide, compound **84**, decreased activity. In general, compounds **87** and **88** were found more active than their non-cyclized counterparts, compounds **85** and **86**, demonstrating that cyclization of thiosemicarbazide-containing compounds into [1,2,4]-triazoles resulted in more substantial and more robust antitumor activity. Furthermore, compound **89** had lower activity than compounds **87** and **88**, indicating that the free sulfanyl group (–SH) had greater potency. In contrast to compound **89**, compound **90** was very active as an anticancer drug, implying that the piperazine moiety enhanced antitumor activity. Similarly, including a piperazine moiety in compounds **91** and **92** resulted in high activity (Fig. 18).

In contrast, the 1-phenylpiperazine, a methoxy group at the fourth position, decreased absorbance, rendering molecule **92** more efficient than molecule **91**. This demonstrated that enhanced activity may occur when a piperazine moiety is modified at place four with a phenyl ring modified with an electron-donating compound, but not when an electron-withdrawing group or even with an unsubstituted group. It

has been demonstrated that compound **93**'s methoxy group on fourth place of the Schiff base aromatic ring was more active than compound **94**'s nitro group. The presence of an electron-donating group on an aromatic nucleus is associated with increased anticancer action in part.[62]

3.4 BCR-ABL kinase

BCR-ABL is a mutation that results from the interaction of two genes, BCR and ABL. It is also known as a fusion gene. The BCR and ABL are present on chromosomes 22 and 9, respectively. When portions of the BCR and ABL genes break off and swap locations, the BCR-ABL mutation occurs. BCR-ABL genes were found in patients with certain types of leukemia and also detected in almost all patients with chronic myeloid leukemia (CML).[63] Loss of auto-inhibition and constitutional activation of ABL1 may occur when the mutant BCR-ABL1 protein arises, with subsequent effects on signalling pathways related to cell cycle and apoptosis, such as the RAS/RAF/MEK/ERK pathway, the JAK2/STAT pathway, and the PI3K/AKT/mTOR pathway. Finally, it promotes the malignant transformation of hematopoietic cells.[64] pyrido[2,3-*d*]pyrimidine are effective tyrosine kinase c-Abl and Bcr/Abl inhibitors. At an IC$_{50}$ 2.5 nM, PD180970 reduced Bcr/Abl tyrosine phosphorylation and triggered death in the human CML cell line K562 [43]. PD180970 was also effective against imatinib mesylate-resistant K562 cells and

Piritrexim (PTX)(76) **Piritrexim analogue 8 (77)** **Piritrexim analogue 12 (78)**

Iso-piritrexim (79) **80** **81**

R= C_2H_5, 4-F-C_6H_4, 4-Cl-C_6H_4

82

Fig. 17 Pyrido[2,3-*d*]pyrimidine derivatives reported as antitumor agents.

Ba/F3-P210 cells expressing BCR/ABL kinase domain mutations observed in imatinib mesylate-resistant CML patients.[65] Compared to imatinib mesylate, PD173955 suppressed the growth of the Bcr/Abl cell line R10(−) with an IC_{50} of 2.5 nM.[66] PD166326 (**95**) was the most potent inhibitor of CD34+ CML progenitor development among the six pyridopyrimidines studied, with an IC_{50} around 4-fold lower than PD173955. With an IC_{50} of 300 pM in K562 cells, PD166326 (**95**) reduced proliferation[66] and demonstrated action against numerous imatinib mesylate-resistant Bcr/Abl mutants.[66,67] western blot analysis of Bcr-abl autophosphorylation on K562 cells revealed that PD166326 (**95**) inhibited Bcr-abl activity in cells. In these cells, IC_{50} for the suppression of Bcr-abl autophosphorylation was 1 nm as compared with 100 nm for STI571. The biological activity and potency of PD166326 (**95**) was tested in K562 cells in cell growth assays. With an IC_{50} of 0.3 nm, compound **95**

suppressed K562 cell growth. Additional hematopoetic and epithelial cell lines were only inhibited at two to three log higher doses with IC_{50}s in the 0.8–2 nm range, indicating that PD166326's powerful biological activity was highly selective for Bcr-abl-driven cells.[68] Bubnoff *et al.* tested 13 different pyridopyrimidine derivatives against wild-type as well as mutant BCR-ABL. All the compounds decreased the Bcr-Abl dependent phenotype more effectively than imatinib and inhibited Bcr-Abl kinase activity (Table 1). PD166326 (**95**) and SKI DV-M016 (**96**) were the most active compounds. Surprisingly, these drugs repressed Bcr-Abl H396P, a mutant with an activation loop, just as well as wild-type Bcr-Abl (Fig. 19).[65]

3.4.1 Mechanism of action of BCR-ABL inhibitors:-. BCR-ABL inhibitors compete with adenosine triphosphate (ATP) for the same binding site inside the BCR-ABL protein's kinase domain. When ATP is present in the binding site, BCR-ABL can

83: R= COOCH$_3$
84: R= CONHNH$_2$

85: Ar= C$_6$H$_5$
86: Ar= 4F-C$_6$H$_5$

87: Ar= C$_6$H$_5$
88: Ar= 4F-C$_6$H$_4$

89

90: Ar= 4F-C$_6$H$_4$

91: R= C$_6$H$_4$
92: R= 4-(CH$_3$O)-C$_6$H$_4$

93: R= 4-OCH$_3$
94: R= 3-NO$_2$

Fig. 18 Pyrido[2,3-d]pyrimidines reported as antitumor agents.

Table 1 Bcr–Abl kinase inhibitory activity of compounds **95** and **96**

Name	IC$_{50}$ value (nM) (mean $\pm$ SE)
SKI DV-M016(**96**)	4.2 $\pm$ 0.6
PD 166326(**95**)	4.3 $\pm$ 0.8

catalyze the phosphorylation of tyrosine residues on substrate proteins. These BCR-ABL inhibitors (Imatinib mesylate) have a structure similar to ATP and can bind to the BCR-ATP-binding ABL's region. Because BCR-ABL inhibitors lack the necessary phosphate groups given by ATP, phosphorylation of tyrosine residues on substrate proteins is impossible. Unphosphorylated tyrosine residues in substrate proteins prevent them from adopting the required conformation for binding to effector molecules. As a result, downstream signal transduction pathways important for CML leukemogenesis are blocked (Fig. 20).[69]

3.5   p38 mitogen-activated protein kinases

p38 Mitogen-activated protein kinases (p38 MAPKs) are proline-directed serine/threonine kinases that regulate pro-inflammatory signalling networks and are involved in the production of cytokines such as tumour necrosis factor-a (TNF-a) and interleukin-1b (IL-1b).[70,71] Four isoforms of p38 MAPK have been found, namely α, β, γ, and δ, with p38a MAPK being the earliest identified, best described, and most significant isoform involved in the inflammatory response.[72] The N- and C-terminal domains of p38a MAPK form the walls of a deep cleft in which the ATP cofactor is allocated in a pocket known as the ATP binding site.[73] The adenine ring of ATP formed hydrogen bonds with His107 as well as Met109 residues of the p38α MAPK backbone. These two residues are found in the hinge region (residues **106–110**), which connects the N and C-lobes, whereas the adenine binding region and ribose pocket, respectively, are located in the adenine binding region and ribose pocket, respectively.[74] The dual interaction of ATP with the hinge region aligns the two protein lobes to produce a pocket large enough to hold the ATP triphosphate group; this pocket is known as the phosphate binding area and contains highly conserved kinase residues like Glu71 and Asp168.[75] Three more hydrophobic areas have been discovered adjacent to the ATP binding site but are not directly involved in ATP binding (Fig. 6).[76] The first section is known as hydrophobic region I (HR-I), and it is

PD166326 (**95**)

SKI DV-M016 (**96**)

Imatinib mesylate (**97**)

Fig. 19 Pyrido[2,3-*d*]pyrimidine derivatives as BCR-ABL kinase inhibitors.


Fig. 20 Mechanism of action of BCR-ABL inhibitors.

defined by Leu75, Lys53, Ala51, Leu104, Ile84, Leu167, and Thr106. It is placed at the back of the ATP binding site (Fig. 21).[77] Because similar kinases have a bulkier residue at the same position, the tiny size of the gatekeeper residue Thr106 allows access to this pocket, which is essential for kinase inhibitor selectivity. The hydrophobic region II (HR-II), a solvent-exposed hydrophobic area defined mainly through residues Val30, Ile108, Gly110, Ala111, and Asp112, is the second section.[78] The allosteric site is located next to HR-I and is only accessible when the kinase adopts the catalytically inactive conformation (DFG-out), in which the highly conserved Asp168-Phe169-Gly170 (DFG) motif is flipped "out" in comparison to its active state conformation (DFG-in).[79]

3.5.1 Structure–activity relationship of P38α inhibitors. The 6th-substituent substantially influences inhibitors' pan-kinase selectivity. In terms of potency, this position is also critical. 6-Aryl substituents, such as *o*-chlorophenyl in compound **98**, are generally potent compared to 99 (Table 2). Phenoxy substituents were chosen because of their high activities and intriguing profile of kinase selectivity. SAR revealed that the phenoxy group found having tiny ortho and para substituents are preferred over no and meta substitutions. The ortho and para difluoro substitution improved the side chain's metabolic stability. At the 8th-position of the scaffold, many different side chains are allowed, reinforcing the idea that this variable points towards solvent. The kinase selectivity of 2-alkylamino side chains was higher than that of 2-anilino side

Fig. 21 Representation of ATP within p38a MAPK binding site of APT. AS: allosteric site; RP: ribose pocket; AR: adenine region; HR-I and HR-II: hydrophobic regions I and II; PR: phosphate region.

Table 2 IC$_{50}$ (nM) of compounds **98** and **99** as P38α inhibitors

Compound	X	R$_1$	R$_2$	R$_3$	Assay IC$_{50}$ (nM) P38α inhibition
98	O	2,4,-diF	CH$_3$	4-Tetrahydropyranyl	10 ± 4
99	O	2,4,-diF	CH$_3$	CH(CH$_2$CH$_2$OH)$_2$	14 ± 2

chains. The molecule's potency was increased by substituting the 4-tetrahydropyranyl group in the second position (Fig. 22).[22]

p38 is one of many kinases implicated in a stress-response signaling pathway similar to but not identical to the MAP kinase cascade. Phosphorylation of threonine 180 and tyrosine 182 by stress signals activates p38. MAPKAP kinase-2 and MAPKAP kinase-3 have been found as downstream targets of p38, which phosphorylates heat shock protein (Fig. 23).[22]

Dilmapimod (**100**, CAS 444606-18-2) is a p38 MAP-kinase inhibitor patented by SmithKline Beecham Corporation (GSK-

Fig. 22 Relationship between structure-modifications and an P38α inhibitors properties.

Fig. 23 Mechanism of p38 inhibitors.

681323) in 2001 and was used in clinical studies for inflammation, neuropathic pain, and cardiac problems but was eventually ceased due to liver damage.[16] Clinical research examined TAK-733 (**101**, CAS 1035555-63-5), a MEK1 and MEK2 (MEK1/2) inhibitor, for advanced non-hematologic malignancies, including metastatic melanoma. It was created and

R1487 (98)

Pamapimod (99)

100

101

Fig. 24 Structures of compounds having p38 inhibitory activity.

patented by Takeda Pharmaceutical Company in 2007. TAK-733 was tested against non-small cell lung cancer and progressed to Phase I before being recalled off the market in 2015 (Fig. 24).[16]

3.6 Phosphatidylinositol 3 kinase and mTOR protein

The phosphatidylinositol (PI) second messengers PI(3)P, PI(3,4)P2, and PI(3,4,5)P3 are produced by phosphoinositide 3-kinase (PI3-KS) enzyme (PIP3). The Class I PI3-KC isoform, which consists of catalytic (p110C) and adapter (p85) subunits is the most common PI3-kinase isoform. By producing 3-phosphorylated phospholipids (PIPs), PI3-KS activates kinases with lipid-binding domains, such as pleckstrin homology (PH) regions, which function as second messengers. For example, Akt as well as phosphoinositide-dependent kinase-1, Akt is moved to the cellular membranes when it links to membrane PIPs, which bind with PDK1 and becomes activated. A tumour suppressor protein, PTEN, dephosphorylates PIP, inhibiting the activation of Akt. The Akt, PDK1, and PI3-Ks are crucial players in controlling numerous cellular functions, including motility, proliferation, survival, and apoptosis. They are also crucial for disease-related molecular pathways, such as cancer, diabetes, and immune-mediated inflammation. Oncogenesis is linked to several components of the PI3K/Akt/PTEN pathway.[80]

In 2007, Pfizer received a patent for compound **102**, inhibiting the mTOR protein and phosphatidylinositol 3 kinases. Due to undesirable effects, it's clinical trial to treat endometrial cancer was stopped in 2012. N68 has also been tested in clinical trials for early (Phase 2) and late breast cancer (Phase 1b).[16] Finally, Voxtalisib (CAS 934493-76-2) (**103**), a kinase inhibitor of PI3K and mammalian target of rapamycin in the PI3K/mTOR signaling cascade was patented by Exelis (XL-765) in 2006. In 2018, withdrawal of voxtalisib as a monotherapy and combo therapy for solid tumors (breast and ovarian cancer) took place due to serious side effects (Fig. 25).[16]

In the discovery of anticancer therapies, the mammalian target of rapamycin (mTOR) is a critical target.[81] The growth factor/mitogenic activation of the phosphatidylinositol 3-kinase

(PI3K/Akt) signalling pathway activates this key regulator of cell growth and proliferation, frequently dysregulate route responsible for diseases. Serine and theonine kinases are the 2 mTOR found in the mammalian body. It's about 289 kDa in size and belongs to the evolutionary family. The eukaryotic PI3K like kinase (PIKK) family of proteins is highly conserved.[82–84]

3.6.1 Mammalian target of rapamycin pathway. The rapamycin and its analogues (RAD001, CCI-779, AP23573) bind to the FKBP12/rapamycin complex binding domain (FRB) and suppress signaling downstream substrates p70S6K and 4E-BP1.[84–86] LY294002 and wortmannin, potent but non-specific PI3K inhibitors, have also been demonstrated to block the kinase activity of mTOR by targeting the protein's catalytic domain.[87] According to the Brunn *et al.* and Edinger *et al.* mTOR is divided into two complexes: mTORC1, a rapamycin-sensitive complex that signals to p70S6K and 4E-BP1, and mTORC2, a rapamycin-insensitive complex that signals to Akt.[87,88] Therefore, direct targeting of the mTOR kinase domain would suppress signalling *via* both mTORC1 and mTORC2 and such a drug would have a distinct pharmacological spectrum than rapamycin (Fig. 26).[84]

3.6.2 Structure–activity relationship of mTOR inhibitors. The dimethyl substitution at C_2 of the morpholino group balances the compound's, resulting in strong mTOR inhibitory activity (Table 3). The presence of the morpholino group is required for mTOR inhibitory activity. The oxygen in this group mediates the H-bond interaction with the mTOR kinase. The potency is significantly reduced due to the slight change in structure and increase in bulk. The combination of an electron donor at the para position with a hydrogen bond donor at the meta position in the phenyl ring exhibited a strong mTOR inhibitory effect (Fig. 27).[84]

The KU-63794 (compound **108**) indicated that mTOR selectivity has been achieved compared to other PIKK family members. Furthermore, it exhibited no significant activity when tested on 200 kinases (non-PI3K related) at a concentration of 10 μM. U87MG glioblastoma cells were treated with the KU-63794 (**108**) for 2 h to see whether it inhibited both mTORC1


102

103

Fig. 25 Pyrido[2,3-*d*]pyrimidine derivatives (**102** and **103**) as PI3K/mTOR inhibitors.

Fig. 26   The mTOR kinase inhibition in the mTOR-PI3K-AKT pathway.

and mTORC2 complexes in the cellular environment. Using a western blot, the phosphorylation of the direct mTORC2 substrate Akt (Ser473) and the indirectly mTORC1 downstream signalling S6 ribosomal protein (Ser235/236) was determined. The IC$_{50}$s were 0.10 and 0.15 μM for each of the endpoints.

3.7   Targeted inhibition of dihydrofolate reductase

NADPH (Nicotinamide adenine dinucleotide phosphate) serves as a cofactor for dihydrofolate reductase (DHFR), which transforms dihydrofolate (DHF) into tetrahydrofolate (THF). THF is necessary to form *de novo* purine and thymidylate (TMP) during cell growth.[89] Inhibiting DHFR activity causes cell death,[90] making DHFR an essential target enzyme in developing chemotherapy.[91] Antifolates are categorized into two types:

traditional/Classical: Due to the inhibitor's hydrophilic characteristic and glutamate moiety (which prevents the inhibitors from diffusing into cells), an active transport mechanism is needed. However, in the non-classical form, substituting the hydrophilic glutamate moiety with lipophilic groups improves its passive diffusion into cells.[92,93] Dihydrofolate reductase (DHFR), specific kinases, such as the tyrosine-protein kinase transforming protein Abl or MAP kinases, and the biotin carboxylase are the most commonly described biological targets of pyrido[2,3-*d*]pyrimidine derivatives (Fig. 28).[18]

Walaa M. *et al.* (2019) synthesised pyrido[2,3-*d*]pyrimidine derivatives and evaluated their *in vitro* antitumor activity against five human cells lines: HePG2, MCF-7, PC3, HCT-116, and HeLa, using doxorubicin as a positive control. Compounds **112–119** (Fig. 29) showed the highest antitumor

Table 3 Pyrido[2,3-*d*]pyrimidine derivatives with mTOR inhibitory activity

S. No.	Compound	R$_1$	R$_2$	R$_3$	mTOR inhibition IC$_{50}$ (µM)
1	104	*(dimethyl morpholine structure)*	*(morpholine structure)*	—	1.3
2	105	*(methyl morpholine structure)*	*(morpholine structure)*	—	0.69
3	106	*(methyl morpholine structure)*	*(homomorpholine/oxazepane structure)*	—	4.8
4	107	*(dimethyl morpholine structure)*	*(morpholine structure)*	*(4-methylpyridine structure)*	0.22
5	108	*(dimethyl morpholine structure)*	*(morpholine structure)*	*(2-methoxy-5-methylbenzyl alcohol structure)*	0.016

The presence of the morphalino group is required for the activity. The H-bond interaction with the mTOR kinase is mediated by the oxygen present in this group. The potency is significantly reduced due to the little change in structure and increase in bulk.

The addition of aromatic amino substituents increased the potency. The combination of an electron donor at the para position with a hydrogen bond donor at the meta position in the phenyl ring exhibited a strong mTOR inhibitory effect.

The dimethyl substitution in the morpholino group balances the compound's lipophilicity and potency, resulting in strong mTOR inhibitory activity.

Fig. 27 SAR of mTOR inhibitors.

effects and were tested for enzymatic inhibition of the dihydrofolate reductase [compared to the reference medication methotrexate (MTX)] to explain the likely mechanism of action of the observed anticancer activity.[94] Molecule **115** had the highest inhibitory activity at IC$_{50}$ of 6.5 µM among all the tested molecules (IC$_{50}$ of MTX = 5.57 µM, Table 4).

3.7.1 Structure–activity relationship study of DHFR inhibitors. SAR study indicated that pyrido[2,3-*d*]pyrimidine scaffold was essential for activity. If the R was replaced with 2,5-dimethoxy substituents, it acted as PTX, and modification at NH position enhanced the activity. Both NH$_2$ groups were responsible for hydrogen bonding (Fig. 30).

3.8 Apoptosis inducer

3.8.1 Cyclin-dependent kinase (CDK). In cancer, the cell-cycle regulatory mechanism, which is necessary for cellular division, is commonly disturbed, resulting in tumour growth. CDK4/6 inhibition inhibits cell proliferation and suppresses

Fig. 28 Methotrexate (**109**) and pyrido[2,3-*d*]pyrimidine derivatives (**110** and **111**) DHFR inhibitors.

DNA replication in malignancies with functioning retinoblastoma. Many positive and negative regulators closely control cell division and the cell cycle. Mitogenic cues activate and upregulate cyclin D, getting complexed with CDK4/6, caused phospholylation leads to retinoblastoma, allowing bound E2F transcription factors to be released for the cell to divide. The cell cycle is positively regulated by CDKs and their cyclin partners, whereas the cell cycle is negatively regulated by retinoblastoma, other tumour suppressors (p16INK4b, p18INK4c, and p19INK4d), and the CDK-interacting protein/kinase inhibitory protein (Cip/Kip) family. Palbociclib is a CDK4/6 inhibitor effective in preclinical breast cancer models.[95] After identifying cyclin-dependent kinases as essential regulators of cell proliferation, Pfizer Inc. developed palbociclib. Warner–Lambert received a patent for palbociclib in 2003. Palbociclib (pyrido[2,3-*d*]pyrimidin-7(8*H*)-one) interferes with the cell cycle. This inhibitor of CD4 kinase was picked out of the pyridopyrimidine class due to its intriguing structural and pharmacological characteristics. The FDA authorized it to treat HR-positive, advanced HER2-negative, or metastatic breast cancer in March 2015.[95] Protein kinases, CDKs (cyclin-dependent kinases), are crucial for cellular processes. They participate in vital physiological processes like transcription and the cell cycle. Based on sequence similarities, the human genome contains 21 genes that encode CDKs, and five genes that encode

a more distant group of proteins have been identified as CDK like (CDKL) kinases. The current CDK nomenclature includes 11 classical CDKs (CDK1-11), two newly proposed family members (CDK12-13), and additional proteins whose names are based on the presence of a cyclin-binding element (PFTAIRE and PCTAIRE proteins) or simply on sequence similarity to the original CDKs, such as CDC2-like kinases (CDC2L) or Cell cycle-related kinases (CCRK).[96]

Apoptosis means allowing cells to die in a controlled manner. Apoptosis is a tightly controlled process in which cells self-destruct and eliminate undesired or diseased cells. The cell genome fractures, shrinks, and the cell portion disintegrate into smaller apoptotic entities during apoptosis.[97] Cancer cells can potentially resist apoptosis, resulting in uncontrolled cancer development.[98] The standard cellular mechanism called apoptosis keeps the ratio of healthy living cells to healthy dying cells in equilibrium. As a result, triggering apoptosis in cancer cells may be viewed as a cancer therapy strategy that does not harm healthy cells and prevents tumour resistance. As a result, finding novel drugs that target any phase of the cell cycle that leads to apoptosis might be a promising anticancer strategy.[99]

3.8.2 Cyclin-dependent kinase (CDK4/6). Pyrido[2,3-*d*]pyrimidine is a critical component in various bioactive compounds, including anticancer medicines, attributed to cyclin-dependent kinase inhibition.[100,101] Palbociclib is a CDK4/

Fig. 29 Pyrido[2,3-*d*]pyrimidine derivatives as DHFR inhibitors.

Table 4 *In vitro* and *in silico* activity of compound **115** against DHFR

Compound no.	Kinase IC$_{50}$ (μM)	Docking score (kcal/mol)	*In vitro* IC$_{50}$ (μM) MCF-7
115	6.5	−14.2	5.66 ± 0.4
MTX(**109**)	5.57	−14.7	

6 inhibitor licensed by the US Food and Drug Administration to treat breast cancer.[102] Safinaz *et al.*, in 2019, prepared pyrido [2,3-*d*]pyrimidines derivatives and evaluated their cytotoxicity activity against various cell lines, including MCF-7, PC-3, and luA-549 and compared the results with doxorubicin. They synthesized different pyrido pyrimidine derivatives and checked their *in vitro* activity against human cancer lines (breast MCF-7, lungs A-549, and prostate PC-3),[103] Cell cycle analysis,[104]


Fig. 30 SAR of DHFR inhibitors.

Table 5 Effect of compound **116** on Caspase-3

Compound no	Caspase-3 conc. (Pg ml^{-1})	Optical density
Control	43.45	0.103
116	603.4	0.741

Table 6 Docking scores of compounds **116**, **117**, and **118** with PDB ID 5L21

Compound no	Docking score (kcal mol^{-1})	Interactions with amino acids
Palbociclib (**61**)	−12.02	Asp163, Val101
116	−13.24	Val77, Phe164, Val101, Phe98, Asp163
117	−15.40	—

Apoptosis assay,[105] Caspase activation assay,[106] RT-PCR for (Bax, Bcl2,p53, and CDK4/6), and compound **116** showed excellent activity against Caspase-3 (Table 5). Furthermore, compounds **116** and **117** showed an excellent docking score and primary amino acid interaction with selected protein (Table 6 and Fig. 31). Compounds **116** and **117** were observed to promote apoptosis in PC-3 and MCF-7 cells *via* activating Bax, p53, and caspase-3, down-regulating Bcl2 and inhibiting CDK4/6. Furthermore, compound **116** directly inhibited CDK6 with an IC$_{50}$ of 115.38 nM, whereas compound **117** inhibited it with an IC$_{50}$ of 726.25 nM (Table 7).[41]

Table 7 Activity of compounds **116** and **117** on cyclin-dependant kinase-6

Compound no	IC$_{50}$ (nM)
116	115.38
117	726.25
Staurosporin (**118**)	92.78

3.8.3 CDK2 roles in the cell cycle and cancer development. CDKs are key regulators of the cell cycle,[107] and the proper regulation of CDK activity is crucial for the ordered execution of the cell cycle.[108] CDK2/cyclin E expression abnormalities have been seen in colorectal, ovarian, breast, and prostate cancers.[109] CDK2 is involved in many stages of the cell cycle, including DNA repair, gene transcription, the G1-S transition, and G2 progression modulation.[110–112]

3.8.4 The function of CDK2 in the proliferation of cells: -. CDK2 is involved in cell cycle control, transcription activity, and tumor epigenetic alterations. Certain malignancies, such as breast cancer,[113] colo-rectal cancer,[114] glioblastoma,[115] and melanoma[116] may benefit from CDK2 inhibition (Fig. 32).

Cyclin-dependent kinase promotes the progression of the G1 phase into the S phase by phosphorylation of the retinoblastoma protein (RB). The E2F family of transcription factors is activated by the hyperphosphorylation of the RB, which reduces its capacity to regulate growth. Growth repressive signals promote CDK inhibitors from the INK4 and CIP/KIP families, which block G1-S progression. Cyclin and dependent kinase complexes are activated by mitogenic signals.[117,118] Diaa *et al.*,


116

117

Palbociclib (61)

Staurosporin (118)

**Fig. 31** Pyrido[2,3-*d*]pyrimidine derivatives with CDK 4/6 inhibitory activity.

Fig. 32 Role of CDK2 in the cell cycle progression.

Fig. 33 Pyrido[2,3-*d*]pyrimidine derivatives as CDK2 inhibitors.

2011 designed and synthesized 2,5,7-trisubstituted pyrido[2,3-*d*] pyrimidines by introducing a variety of substituents at C-2, C-5, and C-7 of the pyridopyridine ring for a potent and selective inhibitors of CDK2 (competitive inhibitors of ATP binding site) and tested them for CDK2, EGFR inhibitory activities, and cell growth inhibitory activities.[10] Using the design of structural scaffolds addressing ATP interactions, they created pyrido[2,3-*d*]pyrimidine scaffolds (CDK2 inhibitors) using the X-ray crystalline structure of CDK2 (PDB ID: 1HCK). The CDK2 inhibitory and anti-proliferative activity is due to the side chains at the 2nd and 7th positions. The CDK2, CDK4, EGFR, and anti-proliferative activities of the Pyrido[2,3-*d*]pyrimidine derivatives were assessed against SNU638, A431, and HCT116, and the results showed that compounds **119** and **120** were more active than roscovitine with IC$_{50}$ values of 0.3 and 0.09 μM, respectively, which shows that compound **120** has the good anti-proliferative activity. The compounds did not show any significant activity against the EGFR, which shows their selectivity against the CDK2 (Fig. 33).[10]

3.8.5 Structure activity relationship of CDK2 inhibitors. SAR studies realeed that 7-amino group's lipophilic function (LF), such as the benzene, and sulfonamide group, significantly increased the CDK2 inhibitory effect. Further, small (LF) with an electron donating group on position 2 of the pyrido[2,3-*d*] pyrimidine moiety was required for CDK2 inhibitory activity.

3.9 Phosphodiesterase inhibitors

Phosphodiesterase 3 is also known as the cyclic GMP-inhibited PDE family. PDE3A and PDE3B are the two genes in the family, each has numerous splice variants. Harrison *et al.*, Macphee *et al.*, Maurice and Haslam *et al.* were the first to discover PDE3A as a significant PDE isoform in bovine heart and platelets.[119] PDE3 enzymes play a role in modulation of cardiac and vascular smooth muscle contractility. PDE3 inhibitors were once examined for the treatment of heart failure. However, they are no longer being studied for that due to undesired arrhythmic side effects. The PDE3 inhibitor milrinone is licensed for intravenous usage in the treatment of heart failure.[120] Abadi *et al.*, 2013 synthesized 7-(3-bromophenyl)-5-(2-ethoxyphenyl) pyrido[2,3-*d*]- pyrimidin-4-amine and 7-(3-bromophenyl)-5-(2-methoxyphenyl)pyrido[2,3-*d*]- pyrimidin-4(3H)-one by cyclization of 2-amino-6-(3-bromophenyl)-4-(2-ethoxyphenyl) nicotineonitrile and 2-amino-6-(3-bromophenyl)-4-(2-methoxyphenyl)- nicotinonitrile by refluxing with formamide and formic acid respectively.[121] PDEs could be promising targets for tumour cell growth control and apoptosis induction. These are; (I) modification of cyclic nucleotide signaling is known to contribute to one of the pathways regulating growth and operation of tumour cells. (II) Various PDE isozymes are discovered in various cancer tissues, (III) non-selective PDE inhibitors like theophylline or

aminophylline affect the proliferation of cancer cell lines.[122] HMG (Human malignant melanoma) has been found to have PDE3 activity, indicating that it might be a potential target for antineoplastic medications. However, the PDE3-specific inhibitors trequinsin and cilostamide did not affect HMG cell growth.[123] The expansion of colon cancer cells was associated with the upregulation of PDE3B mRNA as well as protein in HT-29 cells. Through the dose-dependent activation of PDE3B, cyclic phosphatidic acid (cPA) reduced Akt phosphorylation, lowering HT-29 cell proliferation. As a result, the cPA-PDE3B-cAMP pathway plays an essential role in colon cancer growth, and cPA could be exploited for colon cancer targeted therapy.[124]

3.9.1 Mechanism of action of phosphodiesterase inhibitors. The cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) signalling systems are among the earliest signalling systems discovered, and are involved in a variety of physiological processes such as visual transduction, cell proliferation and differentiation, cell-cycle regulation, gene expression, inflammation, apoptosis, and metabolic function.[125] Adenylyl-cyclase and guanylyl-cyclase produce cyclic nucleotides when G-protein-coupled receptors and molecules like natriuretic peptide or nitric oxide have been activated. cAMP then activates cAMP-dependent kinase (PKA) and other proteins, regulating biological processes like cell differentiation and proliferation. Proteins are phosphorylated when cGMP activates the cGMP dependent protein kinase (PKG), which is involved in physiological mechanisms like ion channel conductance as well as cell death. Phosphodiesterases 3 (PDEs) regulate cAMP and cGMP intracellular concentrations and their diverse biological consequences by catalyzing their hydrolysis.[122]

Fig. 34 Phosphodiesterase 3 signalling pathway and its inhibitors. NO: nitric oxide; PKA: protein kinase A; GPCR: G-protein-coupled receptors; NPs: atrial natriuretic peptide and B-type natriuretic peptide; AC: adenylate cyclase; EPAC: exchange protein activated by cAMP; PKG: protein kinase G; CNG: cyclic-nucleotide-gated ion channels; pGC: particulate guanylyl cyclase; sGC: soluble guanylyl cyclase.

PDEs can be expressed by every cell type, and their location is crucial in controlling cAMP or cGMP cellular functions.[126] Interference with the cAMP/Cgmp signalling pathway has been linked to tumour growth. Increased intracellular cAMP/cGMP may suppress tumour growth and hence be a protective mechanism against tumour progression.[3] PDE inhibitors that limit cAMP or cGMP hydrolysis have thus been identified as possible anticancer medicines (Fig. 34).[125] However, some cancers, such as adenocarcinoma, can stimulate cell proliferation when cAMP levels are elevated.[127,128]

A cyclized pyridopyrimidone analog (**122**) has an IC$_{50}$ as low as 1.34 μM. With cAMP and cGMP as substrates, these two (**121**, and **122**) molecules efficiently inhibited PDE3. This indicates that for the best anticancer action, suppression of both cAMP, as well as cGMP hydrolysis to boost intracellular concentrations of both signalling molecules may be necessary (Fig. 35). Utilizing cGMP as the substrate, compound **121** had an IC$_{50}$ of 10.9 μM and suppressed PDE3 (Table 8). Creating substrate-specific inhibitors for dual-functioning enzymes like PDE3 is a novel development that opens the way to modify the expression of one substrate instead of another, which may have implications for drug discovery in terms of safety and efficacy.

An adaption of the IMAP (Fluorescence polarization phosphodiesterase assay) was used to detect PDE activity.

3.9.2 Relationship between structure-propeties and anticancer activities. The cyclized pyridopyrimidone derivative **121** reduced the tumour cell proliferation, with an IC$_{50}$ of 1.34 μm (Fig. 36). With cAMP and cGMP as substrates, these three drugs efficiently inhibited PDE3. This indicated that the best strategy to treat cancer may be to limit both cAMP as well as cGMP hydrolysis to increase intracellular concentrations of both secondary messengers. The positive control milrinone's inability to cause apoptosis in the HT-29 cell line despite its dual inhibition of PDE3 and growth suggested that the other PDE and off proteins may contribute to the anticancer activity. Alkoxy and Bromo substituents at the ortho positions of the phenyl at positions 4 and 6, respectively, are believed to be responsible for the non-coplanarity between the two aryls and pyridone. The enforcement of bromophenyl non-coplanarity appears to be necessary for stacking with Phe991. Replacement of the oxygen atom of cyano-2-pyrones with an amino group may create the foundation for substrate-selective pharmacological regulation of this significant class of therapeutic targets (Fig. 35).[121]

Fig. 35 SAR of phosphodiesterase inhibitors.

Table 8 Inhibitory activity of compounds **121** and **122** on Cell Line (HT-29) and phosphodiesterase 3B

| Compound no. | HT-29 | | PDE3 inhibition | | | |
| | | | % PDE3 inhibition at 50 μm | | IC$_{50}$ μm | |
	% Growth inhibition at 50 μm	IC$_{50}$ μm	cAMP	cGMP	Camp	cGMP
121	86.10	18.27	48	85	ND	10.91
122	97.98	1.34	62	78.6	24.21	10.75
Milrinone (**123**)	10	>50	77	95	11.4	3.6

Fig. 36 Pyrido[2,3-*d*]pyrimidine derivatives, **122** and **123** with milrinone as phosphodiesterase inhibitors.

3.10 Gene Kirsten rat sarcoma viral oncogene homolog inhibitors

The Gene Kirsten rat sarcoma viral oncogene homolog is known as KRAS. It belongs to the group of epidermal growth factor receptor (EGFR) kinase. This multi-component signaling system helps to regulate cell growth, division, survival, and death by relaying signals from the outside to the inside of the cell. An essential signal for cellular differentiation in normal cells is the interaction of the epidermal growth factor to its target, mainly on the cell membrane. There are two more signals in the process including tyrosine kinase enzymes as well as a protein encoded by the KRAS gene, instead of separately promoting cell proliferation, the route's components typically cooperate to control cell division and growth. KRAS mutations are frequently linked to resistance to targeted medicines and poor outcomes in cancer patients, yet after more than three decades of research, no selective KRAS inhibitor has been authorized. However, in some tumors, EGFR becomes active even when EGF is not present, resulting in uncontrolled cell proliferation and division. EGFR or tyrosine kinase enzyme inhibitors are frequently used to treat these malignancies. However, an alteration in the KRAS gene found in a few of these malignancies leads to an abnormal K-Ras enzyme. The uncontrolled protein is constantly active and can promote cell growth despite the lack of signals from EGFR as well as other tyrosine kinase enzymes. Inhibitors

of EGFR or tyrosine kinases will be ineffective in such tumours.[129–131] KRas is the most often mutated oncogene among all types of human cancer. After the initial discovery of Ras oncogenes in 1982, In Ras-driven cancer, no approved medication specifically targets Ras.[132] Ras proteins are chemical messengers that alternate between an active GTP-bound as well as an inactive GDP-bound state to control a number of cellular functions. Guanine nucleotide exchange factors (GEFs) enhance activation, and GTPase-activating proteins (GAPs) inactivates Ras protein by catalyzing GTP hydrolysis and are involved in these state changes.[133,134] Ras protein mutations result in anomalies in the switch mechanism, a significant contributor to tumorigenesis. RAS mutations are present in three of the most lethal kinds of human malignancy, or around 25% of human tumors, including pancreatic cancer, and colon and lung cancer. KRas is the most frequently altered isoform of the Ras proteins (85%), followed by NRas (11%) and HRas (4%), with the most common mutations occurring at amino acid positions G12, G13, and Q61.[132] Mutations at positions 12 and 13, which cause a steric clash with the catalytic arginine finger donated by the GAPs, are thought to be oncogenic. In contrast, mutations at position 61 disrupt the coordination of a nucleophilic water molecule, resulting in an accumulation of active GTP-bound Ras proteins in cells.[135,136] The Shokat laboratory discovered the switch-II pocket in 2013, creating an opportunity


Fig. 37 Chemical structure of pyrido[2,3-*d*]pyrimidine derivatives **125**, with **124**, & MRTX849 (**126**) as KRAS inhibitors.

for the creation of the KRasG[12C] inhibitors, which is investigated in the trials. A library of 480 tethering compounds was screened for covalent binding to KRasG[12C] using a disulfide-fragment-based screening method.[137]

Structure–activity-relationship (SAR) investigations of 6H05, compound 6Ostrem, and KRAS[G12C] in the GDP state resulted in a co-crystal structure with KRAS[G12C]. Because crystallographic study revealed that the ligand does not attach to the nucleotide-binding pocket (S-IIP), it was given the switch-II pocket and placed near the activator binding switch-II. S-IIP is positioned between the core-sheet and switch-II, and when ligand binding occurs, it undergoes significant conformational changes to form a separate pocket, whereas switch-I conformation remains intact from the GDP-bound state.[132] Many novel covalent allosteric KRAS[G12C] inhibitors have been created as a result of this pioneering work, including ARS1620 (124),[138] AMG510 (125),[139,140] and MRTX849 (126),[141,142] with AMG510 being the first KRAS[G12C] inhibitor to reach clinical trials in August 2018 (Fig. 37). The findings of a phase I trial using this medication were recently released, revealing partial responses in 50% of non-small cell lung cancer (NSCLC) patients and stable disease in the majority of colorectal or appendix cancer patients, all of whom carried the KRAS[G12C] mutation.[143]

Xiao *et al.*, 2021, designed new KRAS[G12C] inhibitors using a novel approach. Two sets of pyrido[2,3-*d*]pyrimidine- and pyridinyl N-atom-shifted bicyclic pyrido[4,3-*d*]pyrimidine-containing derivatives of the clinical KRAS[G12C] inhibitor AMG510 (125) were produced (Fig. 38). MIA PaCa-2 cells, clinical pancreatic cancerous cells with the KRAS[G12C] mutations, were used to test the tetracyclic derivatives; investigating potential off-target effects, the inhibitory activity on A549 cells carrying other KRAS mutant G12S has also been investigated. Although compound 128 demonstrated considerable efficacy, including an IC$_{50}$ value of 7.97 μM in MIA PaCa-2 cell line expressing KRAS[G12C], the tetracyclic molecules still exhibited selectivity toward the G12C mutation of KRAS (Table 9). According to the docking study, the shadow connection between 128 in the front entry and an open hydrophobic pocket

Table 9 Antiproliferative effects of 127 and 128 against MIA PaCa-2 cell lines

Compound no	Ln	R$_1$	R$_2$	R$_3$	IC$_{50}$
127	L1	H	CH$_3$	H	>10 μM
128	L1	H	F	F	7.97 μM
AMG510 (125)	—	—	—	—	0.029 μM

may be the main reason for its less efficacy. The piperazine derivative was less effective than the 3,8-bicyclo[3.2.1]octane linker in the parent skeleton. However, it was found that the piperizinyl linker, which joins the bond formation warhead towards the tetracyclic nucleus, had some biological efficacy. Compounds 127 and 128 have the most effective R$_2$-substituents, such as methyl or fluoro group.[143]

The more robust character of (pyrido[4,3-*d*]pyrimidin) in comparison to 128 (pyrido[2,3-*d*]pyrimidin), explained by fluorophenol group engaging a hydrophobic pocket and creating an H-bonds to Arg68. Additionally, the fluorophenol molecule appeared to occupy the space by the tiny fluoro group at the C-8 place (as in ARS1620). Only molecule 128 showed minor activity in the MIA PaCa-2 human cell expressing KRAS[G12C], with IC$_{50}$ of 7.97 μM, whereas the tetracyclic molecules still showed specificity for the G12C form of KRAS. According to structural docking study, the shadow contact of 127 at the front entry and an unoccupied hydrophobic pocket may be the primary cause of its weak potency. In biochemical and cellular experiments, bicyclic compound 128 was found to be substantial inhibitor.[143]

3.11 Fibroblast growth factor receptors inhibitors

Several endothelial and tumour cells contain tyrosine kinases called FGFR (fibroblast growth factor receptors). They participate in tumour angiogenesis, tumour cell migration, survival, and proliferation. Many human malignancies have been connected to FGFR overexpression or aberrant activity control. As a result, reducing tumor cell proliferation, survival, and migration, as well as tumor angiogenesis by targeting FGFRs is


Fig. 38 SAR of KRAS inhibitors.

an appealing technique for developing cancer therapeutic alternatives.[144] The activation of downstream transduction pathways occurs when the intracellular kinase domain of the FGFRs undergoes transautophosphorylation due to the binding of FGFs, which also causes the dimerization of FGFRs.[145,146] FGFRs contribute to crucial physiological activities, including cell migration, proliferation, differentiation, and survival, *via* activating downstream signalling pathways.[147–149]

3.11.1 FGFR signaling pathways. FRS2, a prominent FGFR substrate, binds to the juxta membrane area of FGFR constitutively *via* its phospho-tyrosine binding domain (PTB), regardless of the kinase domain's activity or phosphorylation state. Several tyrosine residues in FRS2 are phosphorylated after FGFR activation and serve as docking sites for the following molecules.[150] The RAS-MAPK-ERK signalling cascade is repeatedly activated by FRS2. RSA was chacterised by docking with different proteins, including SHP2 (SH2-containing tyrosine kinase phosphatase), GRB2 (growth factor receptor-bound protein 2), SOS (Son of Sevenless). The Src symmetry domain (SH2 domain) in SHP2 as well as GRB2 could bind directly phosphorylated tyrosine residues in GRB2 and FRS2. As a result,

either directly or through the creation of the SHP2-GRB2-SOS complex, the GRB2-SOS complex is recruited to FRS2.[151,152] In the RAS-MAPK-ERK signalling pathway, the complex then initiates a phosphorylation cascade. ERK1/2 is translocated from the cytoplasm to the nucleus after activation. It regulates the activity of various transcription factors to influence cell proliferation, differentiation, and signal transduction, making it one of the most persuasive signalling molecules in this pathway.[153] When GRB2-related binding protein 1 (GAB1) binds to GRB2's SH3 domain, it can phosphorylate tyrosine itself and be dragged into the complex. Similarly, PI3K with an SH2 domain binds to the phosphorylated tyrosine residues of GRB2, activating the PI3K-AKT signalling cascade. AKT's downstream effector molecules include the well-known mTOR, which is involved in cell metabolism, transcription, and other processes (Fig. 39).[154]

In addition to FGFR, PIP2 (phosphatidylinositol 4,5-bisphosphate) is hydrolyzed by phospholipase C, which connects to a phosphorylated tyrosine in the kinase domain's C-terminus to produce the secondary mediators IP3 (inositol triphosphate) and DAG (diacyl glycerol). When IP3 binds to its


Fig. 39 FGFR signaling cascade.

Addition of an amino side chain to the 2-position increases potency and bioavailability of the compounds

Substitution of diphenyl moiety at 6th C increases the selectivity of the compounds aganist FGFR tyrosine kinase receptor

Presence of urea moiety is necessary for good TKI potency. Addition of Larger urea groups resulted in an overall decrease in activity

Fig. 40   SAR of FGFR inhibitors.

receptor on the endoplasmic reticulum, Ca^{2+} is released from intracellular reserves, increasing Ca^{2+} concentration.[155] DAG activates the PKC signalling pathway when it is coordinated with Ca^{2+}, which produces crosstalk with the RAS-MAPK pathway (due to the rivalry between GRB2 and PLCγ) for FGFR binding.[156]

Connolly *et al.* from the Parke-Davis laboratory were the first to identify drugs tailored to target FGFR selectively. The authors used high-throughput screening approaches to find FGFR inhibitors. This led to the discovery of pyrido[2,3-*d*]pyrimidine (**129**), which inhibited FGFR potently (IC_{50} = 0.45 μM) in a biochemical assay; this indicates that the compound **129** binds at the ATP-binding site, and the molecule behaved in an ATP-competitive fashion.[157]

3.11.2   Structure–activity relationship of FGFR inhibitors. SAR analysis revealed the creation of new analogs that were more potent, soluble, and bioavailable than the parent lead. Compound **129** was transformed into compound **131** [by introducing a {4-(diethylamino) butyl} amine substituent], which had a higher potency as well as availability with an IC_{50} of 0.3 μM and reduced PDGF-stimulated vascular smooth muscle cell growth. A selective FGFr tyrosine kinase antagonist, **130**, was also created by substituting 6-(2,6-dichlorophenyl) group of **129** with the 6-(3′,5′-dimethoxyphenyl). If, the pyrido[2,3-*d*]

pyrimidine nucleus has a N′-substituted alkylurea group on the seventh position of parent skeleton, excellent tyrosine kinase antagonists can be synthesiszed.[157] Compound **131** inhibited the FGFr tyrosine kinase with an IC_{50} of 0.060 M, whereas the IC_{50}s for the PDGFr, FGFr, EGFr, c-src, and InsR tyrosine kinases were all greater than 50 μM (Fig. 40 and 41).[157]

4   Summary of anticancer activity of pyrido[2,3-*d*]pyrimidine derivatives

The overall SAR for the anticancer activity of pyrido[2,3-*d*] pyrimidine derivatives is shown below in Fig. 42.

5   Future perspective

Many FDA approved drugs like palbociclib, pamapimod, and piritrexim, having the pyrido[2,3-*d*]scaffold in their structure and are used to treat different form of cancer by *via* inhibiting CDK4/6, p38, and DHFR respectively. AMG510 and R1478 are under phase 1 clinical trails against KRAS and p38 respectively. Dilmapimod (100), TAK-733 (101), and compound 102 have been withdrawn from clinical trials due to undesirable side effects. Therefore, there is need to design selective molecules to

Fig. 41   Structures of pyrido[2,3-*d*]pyrimidine derivatives as FGFR inhibitor.

ortho substituted, furan, thiophene, substituted aryl ring and pyridine

Three to five carbon bridges dimethoxyphenyl, piperidine, paramethoxy phenyl, 2,6-dichlorophenyl, 4-flouropenyl, 3-chloro-benzylbenzamide

Groups position at - 8

groups position at -6

Position at- 4 and 7 groups

(4-CH$_3$- phenyl), (4-chlorophenyl), 2-trifluoromethyl-phenyl

Position at -2,3 groups

5-Methyl-3- oxopyrazole, aminohydrazine phenyl, para-methoxy benzyl, phenylhydrazine, phenyl, trifluoromethyl, COCH$_3$, COOCH$_3$, 2-alkylamino, 6-phenoxy substituent,Alkyltriazole, and aliphatic chain

Fig. 42 Summary of SAR of pyrido[2,3-*d*]pyrimidine derivatives as anticancer agents.

combat resistance and problem of undesirable side effects. In this study, we have found many compounds showed excellent inhibition of cancer at the concentration of nM range. Researchers may design potent and selective molecules keeping in the consideration of sturctural requirements given in structure activity relationship study (Fig. 42).

6   Conclusion

Nitrogen containing heterocyclic compounds, especially pyrido[2,3-*d*]pyrimidines are a diverse class of chemicals having a number of biological properties. Tyrosine kinase, extracellular regulated protein kinases-ABL kinase, phosphatidylinositol-3 kinase, mammalian target of rapamycin, p38 mitogen-activated protein kinases, BCR-ABL, dihydrofolate reductase, Cyclin-dependent kinase, Phosphodiesterase, KRAS (the Gene Kirsten rat sarcoma viral oncogene homolog), and fibroblast growth factor receptors are the reported anticancer tagets of pyrido[2,3-*d*]pyrimidine. These derivatives have demonstrated significant anticancer action upon modifications at C-2, C-3, C-5, C-6, C-7, as well as C-8. Many researchers have explored its Structure activity relationship, as well as conformation and alignment parameters for ligand binding, employing computational modeling as well as docking investigations. The current study also emphasizes a variety of conventional, multi-component, and microwave-assisted approaches for synthesizing pyrido[2,3-*d*]pyrimidine derivatives and will also help scientists find highly effective, precise, and targeted pharmaceuticals.

Conflicts of interest

The authors declare no competing interests.

Author contributions

Conceptualization: P. K., and M. J.; data collection: A. K. S, and H. S.; writing the manuscript: A. K. and K. K. B; sketching of figures: A. K., T. A. and H. S.; data interpretation: A. H. E.; writing, review and final editing of the manuscript: A. V. and H. K.

Acknowledgements

References

1 T. Angre, A. Kumar, A. K. Singh, S. Thareja and P. Kumar, Role of collagen regulators in cancer treatment: A comprehensive review, *Anti-Cancer Agents Med. Chem.*, 2022, **22**, 1–7.

2 R. Weinberg and D. Hanahan, The hallmarks of cancer, *Cell*, 2000, **100**(1), 57–70.

3 L. Torre, R. Siegel and A. Jemal, *Global cancer facts & figures*, American Cancer Society, Atlanta, 2015, 2(3), pp. 1–64.

4 P. Vineis and C. P. Wild, Global cancer patterns: causes and prevention, *Lancet*, 2014, **383**(9916), 549–557.

5 K. M. Abu-Zied, T. K. Mohamed, O. K. Al-Duiaj and M. E. Zaki, A simple approach to fused pyrido[2,3-*d*]pyrimidines incorporating khellinone and trimethoxyphenyl moieties as new scaffolds for antibacterial and antifungal agents, *Heterocycl. Commun.*, 2014, **20**(2), 93–102.

6 R. K. Robins and G. H. Hitchings, Studies on condensed pyrimidine systems. XIX. A new synthesis of pyrido [2,3-d] pyrimidines. The condensation of 1, 3-diketones and 3-ketoaldehydes with 4-aminopyrimidines, *J. Am. Chem. Soc.*, 1958, **80**(13), 3449–3457.

7 Y. Yamamoto, Science of Synthesis, Houben-Weyl Methods of Molecular Transformations; Six-Membered Hetarenes with Two Identical Heteroatoms, *Sci. Synth.*, 2004, 1–1568.

8 A. Gangjee, O. O. Adair and S. F. Queener, Synthesis and Biological Evaluation of 2, 4-Diamino-6-(arylaminomethyl) pyrido [2,3-d]pyrimidines as Inhibitors of Pneumocystis c arinii and Toxoplasma g ondii Dihydrofolate Reductase and as Antiopportunistic Infection and Antitumor Agents, *J. Med. Chem.*, 2003, **46**(23), 5074–5082.

9 H. S. Elzahabi, E. S. Nossier, N. M. Khalifa, R. A. Alasfoury and M. A. El-Manawaty, Anticancer evaluation and molecular modeling of multi-targeted kinase inhibitors based pyrido [2,3-d]pyrimidine scaffold, *J. Enzyme Inhib. Med. Chem.*, 2018, **33**(1), 546–557.

10 D. A. Ibrahim and N. S. Ismail, Design, synthesis and biological study of novel pyrido [2,3-d]pyrimidine as antiproliferative CDK2 inhibitors, *Eur. J. Med. Chem.*, 2011, **46**(12), 5825–5832.

11 T. Yang, H. He, W. Ang, Y.-H. Yang, J.-Z. Yang, Y.-N. Lin, et al., Syntheses and cell-based phenotypic screen of novel 7-amino pyrido [2,3-d]pyrimidine-6-carbonitrile derivatives as potential antiproliferative agents, *Molecules*, 2012, **17**(3), 2351–2366.

12 M. Sako, Product Class 19: Pyridopyrimidines, *Sci Synth*, 2004, **16**, 1155–1267.

13 F. Buron, J. Mérour, M. Akssira, G. Guillaumet and S. Routier, Recent advances in the chemistry and biology of pyridopyrimidines, *Eur. J. Med. Chem.*, 2015, **95**(5), 76–95.

14 B. Evans, K. Rittle, M. Bock, R. DiPardo, R. Freidinger, W. Whitter, et al., Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists, *J. Med. Chem.*, 1988, **31**(12), 2235–2246.

15 C. D. Altomare, Privileged heterocyclic scaffolds in chemical biology and drug discovery: Synthesis and bioactivity, *Chem. Heterocycl. Compd.*, 2017, **53**(3), 239.

16 G. Jubete, R. Puig de la Bellacasa, R. Estrada-Tejedor, J. Teixidó and J. I. Borrell, Pyrido [2,3-d] pyrimidin-7 (8 H)-ones: synthesis and biomedical applications, *Molecules*, 2019, **24**(22), 4161–4182.

17 A. Gangjee, J. Shi, S. F. Queener, L. R. Barrows and R. L. Kisliuk, Synthesis of 5-methyl-5-deaza nonclassical antifolates as inhibitors of dihydrofolate reductases and as potential antipneumocystis, antitoxoplasma, and antitumor agents, *J. Med. Chem.*, 1993, **36**(22), 3437–3443.

18 J. F. Campos, T. Besson and S. Berteina-Raboin, Review on the Synthesis and Therapeutic Potential of Pyrido [2,3-d],[3, 2-d],[3,4-d] and [4, 3-d]pyrimidine Derivatives, *Pharmaceuticals*, 2022, **15**(3), 352–379.

19 A. Gangjee, A. Vasudevan, S. F. Queener and R. L. Kisliuk, 2, 4-Diamino-5-deaza-6-substituted pyrido [2,3-d]pyrimidine antifolates as potent and selective nonclassical inhibitors

of dihydrofolate reductases, *J. Med. Chem.*, 1996, **39**(7), 1438–1446.

20 A. Gangjee, O. O. Adair, M. Pagley and S. F. Queener, N9-substituted 2, 4-diaminoquinazolines: synthesis and biological evaluation of lipophilic inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase, *J. Med. Chem.*, 2008, **51**(19), 6195–6200.

21 E. M. Grivsky, S. Lee, C. W. Sigel, D. S. Duch and C. A. Nichol, Synthesis and antitumor activity of 2, 4-diamino-6-(2, 5-dimethoxybenzyl)-5-methylpyrido [2,3-d] pyrimidine, *J. Med. Chem.*, 1980, **23**(3), 327–329.

22 D. M. Goldstein, M. Soth, T. Gabriel, N. Dewdney, A. Kuglstatter, H. Arzeno, et al., Discovery of 6–(2,4-Difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl) propylamino]-8-methyl-8 H-pyrido [2,3-d] pyrimidin-7-one (Pamapimod) and 6-(2, 4-Difluorophenoxy)-8-methyl-2-(tetrahydro-2 H-pyran-4-ylamino) pyrido [2,3-d] pyrimidin-7 (8 H)-one (R1487) as Orally Bioavailable and Highly Selective Inhibitors of p38α Mitogen-Activated Protein Kinase, *J. Med. Chem.*, 2011, **54**(7), 2255–2265.

23 M. C. Bagley, D. D. Hughes, R. Lloyd and V. E. Powers, A new and highly expedient synthesis of pyrido [2,3-d] pyrimidines, *Tetrahedron Lett.*, 2001, **42**(37), 6585–6588.

24 N. Mont, J. Teixidó, J. I. Borrell and C. O. Kappe, A three-component synthesis of pyrido [2,3-d]pyrimidines, *Tetrahedron Lett.*, 2003, **44**(29), 5385–5387.

25 A. M. Rad and M. Mokhtary, Efficient one-pot synthesis of pyrido [2,3-d]pyrimidines catalyzed by nanocrystalline MgO in water, *Int. Nano Lett.*, 2015, **5**(2), 109–123.

26 A. Shahrzad and B. Saeed, An efficient synthesis of pyrido [2,3-d]pyrimidine derivatives via one-pot three-component reaction in aqueous media, *Int. J. Org. Chem.*, 2012, **2**(1), 7–14.

27 S. Tu, J. Zhang, X. Zhu, J. Xu, Y. Zhang, Q. Wang, et al., New potential inhibitors of cyclin-dependent kinase 4: design and synthesis of pyrido [2,3-d]pyrimidine derivatives under microwave irradiation, *Bioorg. Med. Chem. Lett.*, 2006, **16**(13), 3578–3581.

28 M. K. Paul and A. K. Mukhopadhyay, Tyrosine kinase–role and significance in cancer, *Int. J. Med. Sci.*, 2004, **1**(2), 101–115.

29 P. Blum-Jensen and T. Hunter, Oncogenic kinase signaling, *Nature*, 2001, **411**(3), 355–365.

30 J. Schlessinger, Cell signaling by receptor tyrosine kinases, *Cell*, 2000, **103**(2), 211–225.

31 M. A. Lemmon and J. Schlessinger, Cell signaling by receptor tyrosine kinases, *Cell*, 2010, **141**(7), 1117–1134.

32 Z. Du and C. M. Lovly, Mechanisms of receptor tyrosine kinase activation in cancer, *Mol. Cancer*, 2018, **17**(1), 1–13.

33 J. H. Ludes-Meyers, M. A. Subler, C. V. Shivakumar, R. M. Munoz, P. Jiang, J. E. Bigger, et al., Transcriptional activation of the human epidermal growth factor receptor promoter by human p53, *Mol. Cell. Biol.*, 1996, **16**(11), 6009–6019.

34 T. E. Reznik, Y. Sang, Y. Ma, R. Abounader, E. M. Rosen, S. Xia, et al., Transcription-dependent epidermal growth

factor receptor activation by hepatocyte growth factor, *Mol. Cancer Res.*, 2008, **6**(1), 139–150.

35 Q. Jiao, L. Bi, Y. Ren, S. Song, Q. Wang and Y.-s Wang, Advances in studies of tyrosine kinase inhibitors and their acquired resistance, *Mol. Cancer*, 2018, **17**(1), 1–12.

36 K. S. Kolibaba and B. J. Druker, Protein tyrosine kinases and cancer, *Biochim. Biophys. Acta, Rev. Cancer*, 1997, **1333**(3), 217–248.

37 M. Fares, S. M. Abou-Seri, H. A. Abdel-Aziz, S. E.-S. Abbas, M. M. Youssef and R. A. Eladwy, Synthesis and antitumor activity of pyrido [2,3-*d*]pyrimidine and pyrido [2,3-*d*][1, 2, 4] triazolo [4, 3-a]pyrimidine derivatives that induce apoptosis through G1 cell-cycle arrest, *Eur. J. Med. Chem.*, 2014, **83**, 155–166.

38 R. Rodriguez and M. Meuth, Chk1 and p21 cooperate to prevent apoptosis during DNA replication fork stress, *Mol. Biol. Cell*, 2006, **17**(1), 402–412.

39 L. Cordeu, E. Cubedo, E. Bandrés, A. Rebollo, X. Sáenz, H. Chozas, *et al.*, Biological profile of new apoptotic agents based on 2, 4-pyrido [2,3-*d*]pyrimidine derivatives, *Bioorg. Med. Chem.*, 2007, **15**(4), 1659–1669.

40 M. Font, Á. González, J. A. Palop and C. Sanmartín, New insights into the structural requirements for pro-apoptotic agents based on 2, 4-diaminoquinazoline, 2, 4-diaminopyrido [2,3-*d*]pyrimidine and 2, 4-diaminopyrimidine derivatives, *Eur. J. Med. Chem.*, 2011, **46**(9), 3887–3899.

41 S. E. Abbas, R. F. George, E. M. Samir, M. M. Aref and H. A. Abdel-Aziz, Synthesis and anticancer activity of some pyrido [2,3-*d*]pyrimidine derivatives as apoptosis inducers and cyclin-dependent kinase inhibitors, *Future Med. Chem.*, 2019, **11**(18), 2395–2414.

42 J. M. Hamby, C. J. Connolly, M. C. Schroeder, R. T. Winters, H. H. Showalter, R. L. Panek, *et al.*, Structure–activity relationships for a novel series of pyrido [2,3-*d*]pyrimidine tyrosine kinase inhibitors, *J. Med. Chem.*, 1997, **40**(15), 2296–2303.

43 J. F. Dorsey, R. Jove, A. J. Kraker and J. Wu, The pyrido [2,3-*d*]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells, *Cancer Res.*, 2000, **60**(12), 3127–3131.

44 T. Adon, D. Shanmugarajan and H. Y. Kumar, CDK4/6 inhibitors: a brief overview and prospective research directions, *RSC Adv.*, 2021, **11**(47), 29227–29246.

45 C. Shi, Q. Wang, X. Liao, H. Ge, G. Huo, L. Zhang, *et al.*, Discovery of a novel series of imidazo [1′, 2′: 1, 6] pyrido [2,3-*d*] pyrimidin derivatives as potent cyclin-dependent kinase 4/6 inhibitors, *Eur. J. Med. Chem.*, 2020, **193**, 112239–112259.

46 T. Kong, M. Liu, B. Ji, B. Bai, B. Cheng and C. Wang, Role of the extracellular signal-regulated kinase 1/2 signaling pathway in ischemia-reperfusion injury, *Front. Physiol.*, 2019, **10**, 1038–1048.

47 A. Kohen, Dihydrofolate reductase as a model for studies of enzyme dynamics and catalysis, *F1000Research*, 2015, **4**, 1–8.

48 D. A. Fruman, H. Chiu, B. D. Hopkins, S. Bagrodia, L. C. Cantley and R. T. Abraham, The PI3K pathway in human disease, *Cell*, 2017, **170**(4), 605–635.

49 F. Janku, T. A. Yap and F. Meric-Bernstam, Targeting the PI3K pathway in cancer: are we making headway?, *Nat. Rev. Clin. Oncol.*, 2018, **15**(5), 273–291.

50 L. M. Amzel, C.-H. Huang, D. Mandelker, C. Lengauer, S. B. Gabelli and B. Vogelstein, Structural comparisons of class I phosphoinositide 3-kinases, *Nat. Rev. Cancer*, 2008, **8**(9), 665–669.

51 L. Zhang, Q. Ju, J. Sun, L. Huang, S. Wu, S. Wang, *et al.*, Discovery of novel dual extracellular regulated protein kinases (erk) and phosphoinositide 3-kinase (pi3k) inhibitors as a promising strategy for cancer therapy, *Molecules*, 2020, **25**(23), 5693.

52 H. B. El-Nassan, Synthesis and antitumor activity of novel pyrido [2,3-*d*][1, 2, 4] triazolo [4, 3-a] pyrimidin-5-one derivatives, *Eur. J. Med. Chem.*, 2011, **46**(6), 2031–2036.

53 C. Kurumurthy, P. S. Rao, P. S. Rao, B. Narsaiah, L. Velatooru, R. Pamanji, *et al.*, Synthesis of novel alkyltriazole tagged pyrido [2,3-*d*]pyrimidine derivatives and their anticancer activity, *Eur. J. Med. Chem.*, 2011, **46**(8), 3462–3468.

54 F. Shi, J. Ding, S. Zhang, W.-J. Hao, C. Cheng and S. Tu, Substrate-controlled chemoselective synthesis and potent cytotoxic activity of novel 5, 6, 7-triarylpyrido [2,3-*d*] pyrimidin-4-one derivatives, *Bioorg. Med. Chem. Lett.*, 2011, **21**(5), 1554–1558.

55 N. R. Mohamed, M. M. T. El-Saidi, Y. M. Ali and M. H. Elnagdi, Utility of 6-amino-2-thiouracil as a precursor for the synthesis of bioactive pyrimidine derivatives, *Bioorg. Med. Chem.*, 2007, **15**(18), 6227–6235.

56 M. Zink, H. Lanig and R. Troschütz, Structural variations of piritrexim, a lipophilic inhibitor of human dihydrofolate reductase: synthesis, antitumor activity and molecular modeling investigations, *Eur. J. Med. Chem.*, 2004, **39**(12), 1079–1088.

57 A. Gangjee, O. Adair and S. F. Queener, Synthesis of 2, 4-diamino-6-(thioarylmethyl) pyrido [2,3-*d*]pyrimidines as dihydrofolate reductase inhibitors, *Bioorg. Med. Chem.*, 2001, **9**(11), 2929–2935.

58 V. K. Agrawal, R. Sohgaura and P. V. Khadikar, QSAR studies on biological activity of piritrexim analogues against pc DHFR, *Bioorg. Med. Chem.*, 2002, **10**(9), 2919–2926.

59 T. M. Joska and A. C. Anderson, Structure-activity relationships of Bacillus cereus and Bacillus anthracis dihydrofolate reductase: toward the identification of new potent drug leads, *Antimicrob. Agents Chemother.*, 2006, **50**(10), 3435–3443.

60 D. C. Chan, H. Fu, R. A. Forsch, S. F. Queener and A. Rosowsky, Design, synthesis, and antifolate activity of new analogues of piritrexim and other diaminopyrimidine dihydrofolate reductase inhibitors with ω-carboxyalkoxy or ω-carboxy-1-alkynyl substitution in the side chain, *J. Med. Chem.*, 2005, **48**(13), 4420–4431.

61 C. Sanmartín, M. Echeverría, B. Mendívil, L. Cordeu, E. Cubedo, J. García-Foncillas, et al., Synthesis and biological evaluation of new symmetrical derivatives as cytotoxic agents and apoptosis inducers, Bioorg. Med. Chem., 2005, 13(6), 2031–2044.

62 M. M. Gineinah, M. N. Nasr, S. M. Badr and W. M. El-Husseiny, Synthesis and antitumor activity of new pyrido [2,3-d]pyrimidine derivatives, Med. Chem. Res., 2013, 22(8), 3943–3952.

63 A. L. Nashed, K. W. Rao and M. L. Gulley, Clinical applications of BCR-ABL molecular testing in acute leukemia, J. Mol. Diagn., 2003, 5(2), 63–72.

64 J. V. Melo and M. W. Deininger, Biology of chronic myelogenous leukemia—signaling pathways of initiation and transformation, Hematol. Oncol. Clin., 2004, 18(3), 545–568.

65 M. Huang, J. F. Dorsey, P. Epling-Burnette, R. Nimmanapalli, T. H. Landowski, L. B. Mora, et al., Inhibition of Bcr–Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells, Oncogene, 2002, 21(57), 8804–8816.

66 D. Wisniewski, C. L. Lambek, C. Liu, A. Strife, D. R. Veach, B. Nagar, et al., Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases, Cancer, Res2002, 62(15), 4244–4255.

67 N. Von Bubnoff, D. R. Veach, W. T. Miller, W. Li, J. Sänger, C. Peschel, et al., Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors, Cancer Res., 2003, 63(19), 6395–6404.

68 D. R. Huron, M. E. Gorre, A. J. Kraker, C. L. Sawyers, N. Rosen and M. M. Moasser, A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants, Clin. Cancer Res., 2003, 9(4), 1267–1273.

69 P. Vandenberghe, N. Boeckx, E. Ronsyn, R. Decorte, G. Verhoef and A. Hagemeijer, Imatinib mesylate induces durable complete remission of advanced CML persisting after allogeneic bone marrow transplantation, Leukemia, 2003, 17(2), 458–460.

70 A. Cuadrado and A. R. Nebreda, Mechanisms and functions of p38 MAPK signalling, Biochem. J., 2010, 429(3), 403–417.

71 L. R. Coulthard, D. E. White, D. L. Jones, M. F. McDermott and S. A. Burchill, p38MAPK: stress responses from molecular mechanisms to therapeutics, Trends Mol. Med., 2009, 15(8), 369–379.

72 A. Cuenda and S. Rousseau, p38 MAP-kinases pathway regulation, function and role in human diseases, Biochim. Biophys. Acta, Mol. Cell Res., 2007, 1773(8), 1358–1375.

73 Z. Wang, P. C. Harkins, R. J. Ulevitch, J. Han, M. H. Cobb and E. J. Goldsmith, The structure of mitogen-activated protein kinase p38 at 2.1-Å resolution, Proc. Natl. Acad. Sci. U. S. A., 1997, 94(6), 2327–2332.

74 P. Traxler and P. Furet, Strategies toward the design of novel and selective protein tyrosine kinase inhibitors, Pharmacol. Ther., 1999, 82(2–3), 195–206.

75 S. T. Wrobleski and A. M. Doweyko, Structural comparison of p38 inhibitor-protein complexes: a review of recent p38 inhibitors having unique binding interactions, Curr. Top. Med. Chem., 2005, 5(10), 1005–1016.

76 D. R. Hauser, T. Scior, D. M. Domeyer, B. Kammerer and S. A. Laufer, Synthesis, biological testing, and binding mode prediction of 6, 9-diarylpurin-8-ones as p38 MAP kinase inhibitors, J. Med. Chem., 2007, 50(9), 2060–2066.

77 E. L. Michelotti, K. K. Moffett, D. Nguyen, M. J. Kelly, R. Shetty, X. Chai, et al., Two classes of p38α MAP kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes, Bioorg. Med. Chem. Lett., 2005, 15(23), 5274–5279.

78 S. A. Laufer, D. R. Hauser, D. M. Domeyer, K. Kinkel and A. J. Liedtke, Design, synthesis, and biological evaluation of novel Tri-and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: Focus on optimized interactions with the enzyme's surface-exposed front region, J. Med. Chem., 2008, 51(14), 4122–4149.

79 Y. Liu and N. S. Gray, Rational design of inhibitors that bind to inactive kinase conformations, Nat. Chem. Biol., 2006, 2(7), 358–364.

80 H. Cheng, D. Bhumralkar, K. R. Dress, J. E. Hoffman, M. C. Johnson, R. S. Kania, et al., 4-Methylpyridopy-rimidinone compounds, US Pat., US8273755B2, 2012.

81 S. Huang and P. J. Houghton, Targeting mTOR signaling for cancer therapy, Curr. Opin. Pharmacol., 2003, 3(4), 371–377.

82 T. A. Yap, M. D. Garrett, M. I. Walton, F. Raynaud, J. S. de Bono and P. Workman, Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises, Curr. Opin. Pharmacol., 2008, 8(4), 393–412.

83 E. J. Brown, M. W. Albers, T. Bum Shin, C. T. Keith, W. S. Lane and S. L. Schreiber, A mammalian protein targeted by G1-arresting rapamycin–receptor complex, Nature, 1994, 369(6483), 756–758.

84 K. Malagu, H. Duggan, K. Menear, M. Hummersone, S. Gomez, C. Bailey, et al., The discovery and optimisation of pyrido [2,3-d]pyrimidine-2, 4-diamines as potent and selective inhibitors of mTOR kinase, Bioorg. Med. Chem. Lett., 2009, 19(20), 5950–5953.

85 D. C. Fingar, S. Salama, C. Tsou, E. Harlow and J. Blenis, Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E, Genes Dev., 2002, 16(12), 1472–1487.

86 D. C. Fingar, C. J. Richardson, A. R. Tee, L. Cheatham, C. Tsou and J. Blenis, mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E, Mol. Cell. Biol., 2004, 24(1), 200–216.

87 G. J. Brunn, J. Williams, C. Sabers, G. Wiederrecht, J. Lawrence Jr and R. T. Abraham, Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002, EMBO J., 1996, 15(19), 5256–5267.

88 D. J. VanderWeele and C. M. Rudin, Mammalian target of rapamycin promotes vincristine resistance through

multiple mechanisms independent of maintained glycolytic rate, *Mol. Cancer Res.*, 2005, **3**(11), 635–644.

89 K. Misselbeck, L. Marchetti, M. S. Field, M. Scotti, C. Priami and P. J. Stover, A hybrid stochastic model of folate-mediated one-carbon metabolism: Effect of the common C677T MTHFR variant on *de novo* thymidylate biosynthesis, *Sci. Rep.*, 2017, **7**(1), 1–11.

90 T. C. Alexander, C. M. Simecka, F. Kiffer, T. Groves, J. Anderson, H. Carr, *et al.*, Changes in cognition and dendritic complexity following intrathecal methotrexate and cytarabine treatment in a juvenile murine model, *Behav. Brain Res.*, 2018, **346**, 21–28.

91 L. H. Matherly, Molecular and cellular biology of the human reduced folate carrier, *Prog. Nucleic Acid Res. Mol. Biol.*, 2001, **67**(1), 131–162.

92 H. Li, F. Fang, Y. Liu, L. Xue, M. Wang, Y. Guo, *et al.*, Inhibitors of dihydrofolate reductase as antitumor agents: design, synthesis and biological evaluation of a series of novel nonclassical 6-substituted pyrido [3, 2-d]pyrimidines with a three-to five-carbon bridge, *Bioorg. Med. Chem.*, 2018, **26**(9), 2674–2685.

93 M. Wang, J. Yang, M. Yuan, L. Xue, H. Li, C. Tian, *et al.*, Synthesis and antiproliferative activity of a series of novel 6-substituted pyrido [3, 2-d]pyrimidines as potential nonclassical lipophilic antifolates targeting dihydrofolate reductase, *Eur. J. Med. Chem.*, 2017, **128**, 88–97.

94 O. A. Abdelaziz, W. M. El Husseiny, K. B. Selim and H. M. Eisa, Dihydrofolate reductase inhibition effect of 5-substituted pyrido [2,3-d]pyrimidines: Synthesis, antitumor activity and molecular modeling study, *Bioorg. Chem.*, 2019, **90**(107), 2411–2502.

95 K. A. Cadoo, A. Gucalp and T. A. Traina, Palbociclib: an evidence-based review of its potential in the treatment of breast cancer, *Breast Cancer: Targets Ther.*, 2014, **6**(4), 123–133.

96 M. Malumbres, E. Harlow, T. Hunt, T. Hunter, J. M. Lahti, G. Manning, *et al.*, Cyclin-dependent kinases: a family portrait, *Nat. Cell Biol.*, 2009, **11**(11), 1275–1276.

97 G. Kroemer, L. Galluzzi, P. Vandenabeele, J. Abrams, E. S. Alnemri, E. Baehrecke, *et al.*, Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009, *Cell Death Differ.*, 2009, **16**(1), 3–11.

98 D. Hanahan and R. A. Weinberg, The hallmarks of cancer, *Cell*, 2000, **100**(1), 57–70.

99 J. Plati, O. Bucur and R. Khosravi-Far, Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities, *J. Cell. Biochem.*, 2008, **104**(4), 1124–1149.

100 P. L. Toogood, P. J. Harvey, J. T. Repine, D. J. Sheehan, S. N. VanderWel, H. Zhou, *et al.*, Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6, *J. Med. Chem.*, 2005, **48**(7), 2388–2406.

101 M. Barvian, D. H. Boschelli, J. Cossrow, E. Dobrusin, A. Fattaey, A. Fritsch, *et al.*, Pyrido [2,3-d] pyrimidin-7-one inhibitors of cyclin-dependent kinases, *J. Med. Chem.*, 2000, **43**(24), 4606–4616.

102 N. C. Turner, J. Ro, F. André, S. Loi, S. Verma, H. Iwata, *et al.*, Palbociclib in hormone-receptor–positive advanced breast cancer, *N. Engl. J. Med.*, 2015, **373**(3), 209–219.

103 V. Vichai and K. Kirtikara, Sulforhodamine B colorimetric assay for cytotoxicity screening, *Nat. Protoc.*, 2006, **1**(3), 1112–1116.

104 A. Kamal, T. S. Reddy, S. Polepalli, N. Shalini, V. G. Reddy, A. S. Rao, *et al.*, Synthesis and biological evaluation of podophyllotoxin congeners as tubulin polymerization inhibitors, *Bioorg. Med. Chem.*, 2014, **22**(19), 5466–5475.

105 C. P. Kumar, T. S. Reddy, P. S. Mainkar, V. Bansal, R. Shukla, S. Chandrasekhar, *et al.*, Synthesis and biological evaluation of 5, 10-dihydro-11*H*-dibenzo [b, e] [1, 4] diazepin-11-one structural derivatives as anti-cancer and apoptosis inducing agents, *Eur. J. Med. Chem.*, 2016, **108**, 674–686.

106 V. Gurtu, S. R. Kain and G. Zhang, Fluorometric and colorimetric detection of caspase activity associated with apoptosis, *Anal. Biochem.*, 1997, **251**(1), 98–102.

107 A. W. Murray, Recycling the cell cycle: cyclins revisited, *Cell*, 2004, **116**(2), 221–234.

108 A. Carnero, Targeting the cell cycle for cancer therapy, *Br. J. Cancer*, 2002, **87**(2), 129–133.

109 K. R. Webster and S. D. Kimball, Novel drugs targeting the cell cycle, *Emerging Drugs*, 2000, **5**(1), 45–59.

110 T. Ma, B. A. Van Tine, Y. Wei, M. D. Garrett, D. Nelson, P. D. Adams, *et al.*, Cell cycle–regulated phosphorylation of p220NPAT by cyclin E/Cdk2 in Cajal bodies promotes histone gene transcription, *Genes Dev.*, 2000, **14**(18), 2298–2313.

111 L. De Boer, V. Oakes, H. Beamish, N. Giles, F. Stevens, M. Somodevilla-Torres, *et al.*, Cyclin A/cdk2 coordinates centrosomal and nuclear mitotic events, *Oncogene*, 2008, **27**(31), 4261–4268.

112 O. Flores, Z. Wang, K. E. Knudsen and K. L. Burnstein, Nuclear targeting of cyclin-dependent kinase 2 reveals essential roles of cyclin-dependent kinase 2 localization and cyclin E in vitamin D-mediated growth inhibition, *Endocrinol*, 2010, **151**(3), 896–908.

113 S. Akli, C. S. Van Pelt, T. Bui, L. Meijer and K. Keyomarsi, Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin, *E. Cancer Res.*, 2011, **71**(9), 3377–3386.

114 H. Yamamoto, T. Monden, H. Miyoshi, H. Izawa, K. Ikeda, M. Tsujie, *et al.*, Cdk2/cdc2 expression in colon carcinogenesis and effects of cdk2/cdc2 inhibitor in colon cancer cells, *Int. J. Oncol.*, 1998, **13**(2), 233–242.

115 V. Juric and B. Murphy, Cyclin-dependent kinase inhibitors in brain cancer: Current state and future directions, *Cancer Drug Resist.*, 2020, **3**(1), 48–62.

116 B. M. Desai, J. Villanueva, T.-T. K. Nguyen, M. Lioni, M. Xiao, J. Kong, *et al.*, The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling, *PLoS one*, 2013, **8**(3), 59588–59600.

117 G. Angius, S. Tomao, V. Stati, P. Vici, V. Bianco and F. Tomao, Prexasertib, a checkpoint kinase inhibitor:

from preclinical data to clinical development, *Cancer Chemother. Pharmacol.*, 2020, **85**(1), 9–20.

118 M. Shah, M. F. H. Qureshi, D. Mohammad, M. Lakhani, T. Urooj and S. Mushtaq, CDKs family-a glimpse into the past and present: from cell cycle control to current biological functions, *Asian Pac. J. Cancer Biol.*, 2020, **5**(1), 1–9.

119 J. Beavo, S. H. Francis and M. D. Houslay, *Cyclic nucleotide phosphodiesterases in health and disease*, CRC Press, 2007, p.728.

120 A. T. Bender and J. A. Beavo, Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use, *Pharmacol. Rev.*, 2006, **58**(3), 488–520.

121 A. H. Abadi, M. S. Hany, S. A. Elsharif, A. A. H. Eissa, B. D. Gary, H. N. Tinsley, *et al.*, Modulating the cyclic guanosine monophosphate substrate selectivity of the phosphodiesterase 3 inhibitors by pyridine, pyrido [2,3-*d*] pyrimidine derivatives and their effects upon the growth of HT-29 cancer cell line, *Chem. Pharm. Bull.*, 2013, **61**(4), 405–410.

122 L. Hirsh, A. Dantes, B.-S. Suh, Y. Yoshida, K. Hosokawa, K. Tajima, *et al.*, Phosphodiesterase inhibitors as anti-cancer drugs, *Biochem. Pharmacol.*, 2004, **68**(6), 981–988.

123 T. Murata, K. Shimizu, M. Narita, V. C. Manganiello and T. Tagawa, Characterization of phosphodiesterase 3 in human malignant melanoma cell line, *Anticancer Res.*, 2002, **22**(6A), 3171–3174.

124 T. Tsukahara, Y. Matsuda and H. Haniu, Cyclic phosphatidic acid stimulates cAMP production and inhibits growth in human colon cancer cells, *PloS one*, 2013, **8**(11), e81139.

125 D. H. Maurice, H. Ke, F. Ahmad, Y. Wang, J. Chung and V. C. Manganiello, Advances in targeting cyclic nucleotide phosphodiesterases, *Nat. Rev. Drug Discovery*, 2014, **13**(4), 290–314.

126 I. Levy, A. Horvath, M. Azevedo, R. B. de Alexandre and C. A. Stratakis, Phosphodiesterase function and endocrine cells: links to human disease and roles in tumor development and treatment, *Curr. Opin. Pharmacol.*, 2011, **11**(6), 689–697.

127 H. A. Al-Wadei and H. M. Schuller, Cyclic adenosine monophosphate-dependent cell type-specific modulation of mitogenic signaling by retinoids in normal and neoplastic lung cells, *Cancer Detect. Prev.*, 2006, **30**(5), 403–411.

128 T. Peng, J. Gong, Y. Jin, Y. Zhou, R. Tong, X. Wei, *et al.*, Inhibitors of phosphodiesterase as cancer therapeutics, *Eur. J. Med. Chem.*, 2018, **150**, 742–756.

129 L. Huang, Z. Guo, F. Wang and L. Fu, KRAS mutation: from undruggable to druggable in cancer, *Signal Transduction Targeted Ther.*, 2021, **6**(1), 1–20.

130 P. J. Roberts and T. E. Stinchcombe, KRAS mutation: should we test for it, and does it matter?, *J. Clin. Oncol.*, 2013, **31**(8), 1112–1121.

131 C. Tan and X. Du, KRAS mutation testing in metastatic colorectal cancer, *World J. Gastroenterol.*, 2012, **18**(37), 5171–5180.

132 L. Goebel, M. P. Müller, R. S. Goody and D. Rauh, KRasG12C inhibitors in clinical trials: a short historical perspective, *RSC Med. Chem.*, 2020, **11**(7), 760–770.

133 A. D. Cox, S. W. Fesik, A. C. Kimmelman, J. Luo and C. J. Der, Drugging the undruggable RAS: Mission possible?, *Nat. Rev. Drug Discovery*, 2014, **13**(11), 828–851.

134 I. R. Vetter and A. Wittinghofer, The guanine nucleotide-binding switch in three dimensions, *Science*, 2001, **294**(5545), 1299–1304.

135 K. Scheffzek, M. R. Ahmadian, W. Kabsch, L. Wiesmuller, A. Lautwein, F. Schmitz, *et al.*, The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants, *Science*, 1997, **277**(5324), 333–339.

136 G. Buhrman, G. Holzapfel, S. Fetics and C. Mattos, Allosteric modulation of Ras positions Q61 for a direct role in catalysis, *Proc. Natl. Acad. Sci. U. S. A.*, 2010, **107**(11), 4931–4936.

137 J. M. Ostrem, U. Peters, M. L. Sos, J. A. Wells and K. M. Shokat, K-Ras (G12C) inhibitors allosterically control GTP affinity and effector interactions, *Nature*, 2013, **503**(7477), 548–551.

138 M. R. Janes, J. Zhang, L.-S. Li, R. Hansen, U. Peters, X. Guo, *et al.*, Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor, *Cell*, 2018, **172**(3), 578–589.

139 J. Canon, K. Rex, A. Y. Saiki, C. Mohr, K. Cooke, D. Bagal, *et al.*, The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity, *Nature*, 2019, **575**(7781), 217–223.

140 B. A. Lanman, J. R. Allen, J. G. Allen, A. K. Amegadzie, K. S. Ashton, S. K. Booker, *et al.*, Discovery of a covalent inhibitor of KRASG12C (AMG 510) for the treatment of solid tumors, *J. Med. Chem.*, 2020, 52–65.

141 J. Hallin, L. D. Engstrom, L. Hargis, A. Calinisan, R. Aranda, D. M. Briere, *et al.*, The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and PatientsTherapeutic Insight from the KRASG12C Inhibitor MRTX849, *Cancer Discovery*, 2020, **10**(1), 54–71.

142 J. B. Fell, J. P. Fischer, B. R. Baer, J. F. Blake, K. Bouhana, D. M. Briere, *et al.*, Identification of the clinical development candidate MRTX849, a covalent KRASG12C inhibitor for the treatment of cancer, *J. Med. Chem.*, 2020, **63**(13), 6679–6693.

143 X. Xiao, M. Lai, Z. Song, M. Geng, J. Ding, H. Xie, *et al.*, Design, synthesis and pharmacological evaluation of bicyclic and tetracyclic pyridopyrimidinone analogues as new KRASG12C inhibitors, *Eur. J. Med. Chem.*, 2021, **213**, 1–59.

144 G. Zhao, W.-y Li, D. Chen, J. R. Henry, H.-Y. Li, Z. Chen, *et al.*, A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft ModelsSmall-Molecule Inhibitor of FGFR, *Mol. Cancer Ther.*, 2011, **10**(11), 2200–2210.

145 J. Schlessinger, Cell signaling by receptor tyrosine kinases: From basic concepts to clinical applications, *Eur. J. Cancer Suppl.*, 2006, **4**(6), 3–26.

146 J. Schlessinger, Receptor tyrosine kinases: legacy of the first two decades, *Cold Spring Harbor Perspect. Biol.*, 2014, **6**(3), 1–13.

147 D. M. Ornitz and N. Itoh, The fibroblast growth factor signaling pathway, *Wiley Interdiscip. Rev.: Dev. Biol.*, 2015, **4**(3), 215–266.

148 A. Beenken and M. Mohammadi, The FGF family: biology, pathophysiology and therapy, *Nat. Rev. Drug Discovery*, 2009, **8**(3), 235–253.

149 K. Dorey and E. Amaya, FGF signalling: diverse roles during early vertebrate embryogenesis, *Development*, 2010, **137**(22), 3731–3742.

150 J. Zheng, W. Zhang, L. Li, Y. He, Y. Wei, Y. Dang, *et al.*, Signaling Pathway and Small-Molecule Drug Discovery of FGFR: A Comprehensive Review, *Front. Chem.*, 2022, **10**, 1–24.

151 Y. Hadari, H. Kouhara, I. Lax and J. Schlessinger, Binding of Shp2 tyrosine phosphatase to FRS2 is essential for fibroblast growth factor-induced PC12 cell differentiation, *Mol. Cell. Biol.*, 1998, **18**(7), 3966–3973.

152 S. Ong, G. Guy, Y. Hadari, S. Laks, N. Gotoh, J. Schlessinger, *et al.*, FRS2 proteins recruit intracellular signaling pathways by binding to diverse targets on fibroblast growth factor and nerve growth factor receptors, *Mol. Cell. Biol.*, 2000, **20**(3), 979–989.

153 Y. Guo, W. Pan, S. Liu, Z. Shen, Y. Xu and L. Hu, ERK/MAPK signalling pathway and tumorigenesis, *Exp. Ther. Med.*, 2020, **19**(3), 1997–2007.

154 M.-Y. Quan, Q. Guo, J. Liu, R. Yang, J. Bai, W. Wang, *et al.*, An FGFR/AKT/SOX2 signaling axis controls pancreatic cancer stemness, *Front. Cell Dev. Biol.*, 2020, **8**, 287–302.

155 The IP3 receptor/Ca^{2+} channel and its cellular function, *Biochemical Society Symposia*, ed. M. J. Wakelam and K. Mikoshiba, Portland Press, 2007.

156 A. E. Fearon and R. P. Grose, Grb-ing receptor activation by the tail, *Nat. Struct. Mol. Biol.*, 2014, **21**(2), 113–114.

157 C. J. Connolly, J. M. Hamby, M. C. Schroeder, M. Barvian, G. H. Lu, R. L. Panek, *et al.*, Discovery and structure-activity studies of a novel series of pyrido [2,3-*d*] pyrimidine tyrosine kinase inhibitors, *Bioorg. Med. Chem. Lett.*, 1997, **7**(18), 2415–2420.